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Following	  traumatic	  brain	  injury	  (TBI),	  neuroinflammation	  contributes	  to	  the	  secondary	  
injury.	  	  Microglia	  are	  the	  resident	  immune	  cells	  of	  the	  central	  nervous	  system	  (CNS),	  and	  when	  
activated	  can	  exert	  either	  protective	  or	  detrimental	  effects	  on	  surrounding	  tissue.	  	  They	  are	  
often	  segregated	  into	  subpopulations	  based	  on	  their	  type	  of	  activation,	  either	  pro-­‐
inflammatory	  (M1,	  classically	  activated),	  or	  anti-­‐inflammatory	  (M2,	  alternatively	  activated).	  	  
Minocycline,	  an	  anti-­‐inflammatory	  drug,	  is	  known	  to	  be	  neuroprotective	  and	  to	  have	  effect	  on	  
microglia.	  	  	  However,	  the	  effect	  of	  minocycline	  on	  subpopulations	  of	  inflammatory	  cells	  in	  the	  
acute	  stage	  following	  injury	  is	  unclear.	  	  It	  is	  also	  unclear	  whether	  minocycline	  has	  a	  different	  
treatment	  effect	  on	  injury-­‐induced	  inflammatory	  responses	  in	  young	  and	  aged	  populations.	  	  In	  
this	  study,	  we	  compared	  the	  effect	  of	  minocycline	  treatments	  on	  the	  microglial	  markers	  and	  
the	  M2	  subtype	  in	  both	  young	  (3-­‐month-­‐old)	  and	  aged	  (20-­‐month-­‐old)	  rats,	  sacrificed	  at	  three	  
days	  after	  a	  moderate	  controlled	  cortical	  impact	  (CCI)	  injury.	  	  Minocycline	  treatments	  were	  
either	  given	  beginning	  at	  30	  minutes	  post-­‐injury	  or	  4	  hours	  post-­‐injury	  for	  three	  days.	  	  
Inflammatory	  cell	  markers	  ED1,	  OX6,	  and	  Iba1,	  as	  well	  as	  Arginase	  1,	  a	  marker	  for	  alternatively	  
	   x	  
activated	  macrophages/microglia,	  were	  used	  to	  label	  inflammatory	  cells.	  	  Staining	  intensity	  of	  
each	  marker	  was	  analyzed	  in	  both	  the	  peri-­‐lesion	  cortical	  tissue	  and	  the	  ipsilateral	  hippocampus	  
regions.	  	  Our	  findings	  have	  found	  that	  3-­‐day	  minocycline	  treatment	  significantly	  attenuated	  TBI-­‐
induced	  inflammatory	  cell	  response	  especially	  in	  the	  aged	  rats.	  	  	  Minocycline	  treatment	  did	  not	  
show	  any	  significant	  changes	  in	  the	  prevalence	  of	  the	  M2	  phenotype.	  	  Our	  findings	  suggest	  that	  
minocycline	  may	  exert	  its	  anti-­‐inflammatory	  effect	  mostly	  on	  inhibition	  of	  M1	  phenotype	  rather	  
than	  promoting	  M2	  phenotype.
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INTRODUCTION	  
Traumatic	  Brain	  Injury	  (TBI)	  is	  a	  worldwide	  health	  concern,	  affecting	  an	  estimated	  10	  
million	  people	  yearly	  (Hyder	  et	  al.	  2007).	  	  In	  the	  United	  States	  alone,	  the	  Centers	  for	  Disease	  
Control	  and	  Prevention	  (CDC)	  reports	  that	  there	  are	  about	  1.7	  million	  cases	  annually,	  and	  
that	  TBI	  contributes	  to	  one-­‐third	  of	  all	  injury-­‐related	  deaths.	  	  While	  TBI	  is	  the	  most	  common	  
cause	  of	  death	  in	  young	  people	  (<40	  years	  of	  age),	  it	  is	  also	  a	  major	  problem	  for	  the	  aged	  
population,	  who	  are	  vulnerable	  to	  falls	  (Hyder	  et	  al.	  2007).	  	  TBI	  involves	  not	  only	  the	  primary	  
trauma,	  but	  also	  a	  multi-­‐faceted	  secondary	  injury,	  characterized	  by	  several	  mechanisms	  
including	  neuroinflammation,	  excitotoxicity,	  and	  the	  production	  of	  free	  radicals.	  	  Because	  of	  
the	  extensive	  damage	  associated	  with	  these	  two	  phases,	  hospitalization	  and	  rehabilitation	  
costs	  related	  to	  TBI	  can	  also	  be	  astounding,	  amounting	  to	  over	  $48	  billion	  in	  the	  U.S.	  each	  
year	  (Huang	  2013).	  	  	  	  
It	  is	  widely	  understood	  that	  after	  the	  primary	  injury,	  or	  the	  direct	  tissue	  loss,	  cell	  
death,	  and	  disruption	  of	  the	  blood-­‐brain	  barrier	  (BBB)	  caused	  by	  the	  biomechanical	  impact,	  
a	  secondary	  injury	  extends	  the	  damage.	  	  This	  insult	  is	  caused	  in	  large	  part	  by	  
neuroinflammation	  involving	  the	  activation	  of	  glial	  cells	  and	  the	  accumulation	  of	  leukocytes	  
(Greve	  and	  Zink	  2009).	  	  Microglia,	  the	  resident	  immune	  cells	  of	  the	  central	  nervous	  system	  
(CNS),	  play	  a	  large	  part	  in	  this	  immune	  response.	  	  They	  not	  only	  phagocytize	  cellular	  debris	  
(and	  possible	  pathogens),	  but	  also	  produce	  pro-­‐inflammatory	  cytokines	  as	  well	  as	  growth-­‐
promoting	  factors.	  Microglia	  have	  several	  activation	  phenotypes,	  but	  are	  generally	  classified	  
into	  the	  M1	  and	  M2	  subtypes.	  	  M1,	  also	  known	  as	  classically	  activated	  
microglia/macrophages,	  are	  characterized	  by	  the	  production	  of	  high	  levels	  of	  pro-­‐
inflammatory	  cytokines	  and	  increased	  phagocytic	  activity.	  	  M2,	  or	  alternatively	  activated	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microglia/macrophages,	  are	  distinguished	  by	  the	  production	  of	  high	  levels	  of	  anti-­‐
inflammatory	  cytokines	  and	  growth	  factors,	  as	  well	  as	  other	  neuroprotective	  properties	  
(Fairweather	  et	  al.	  2009).	  	  While	  the	  inflammation	  caused	  by	  TBI	  can	  persist	  for	  days	  to	  
years,	  cytokine	  levels	  can	  increase	  in	  minutes	  following	  injury	  and	  some	  can	  peak	  within	  
hours	  (Jin	  et	  al.	  2012).	  	  Therefore,	  it	  is	  important	  to	  address	  the	  acute	  response	  in	  order	  to	  
limit	  secondary	  injury.	  
After	  childhood,	  incidences	  of	  TBI	  peak	  in	  elderly	  populations,	  and	  past	  65	  years,	  the	  
frequency	  of	  brain	  trauma	  doubles	  every	  10	  years	  (Hyder	  et	  al.	  2007).	  	  In	  general,	  aged	  
individuals	  have	  higher	  morbidity	  and	  mortality	  associated	  with	  TBI,	  as	  well	  as	  lower	  
functional	  recovery	  (Livingston	  et	  al.	  2005).	  	  In	  the	  aged	  brain	  there	  are	  increased	  levels	  of	  
systemic	  inflammation	  and	  a	  prolonged	  inflammatory	  response	  (Stout	  and	  Suttles	  2005),	  
which	  may	  exacerbate	  the	  damage	  incurred	  during	  the	  secondary	  response,	  compared	  to	  
young	  animals.	  	  There	  is	  also	  evidence	  suggesting	  that	  the	  M1	  pro-­‐inflammatory	  phenotype	  
is	  increased	  in	  aged	  mice	  after	  injury,	  when	  compared	  to	  young	  animals	  (Kumar	  et	  al.	  2013).	  	  
These	  changes	  indicate	  that	  suppressing	  the	  inflammatory	  response	  in	  aged	  individuals	  will	  
improve	  outcome.	  
Currently,	  different	  therapies	  to	  treat	  secondary	  injury	  are	  being	  explored.	  	  	  	  
Minocycline	  is	  a	  tetracycline-­‐derived	  antibiotic	  that	  has	  a	  wide	  range	  of	  anti-­‐inflammatory	  
effects.	  	  Minocycline	  is	  known	  to	  reduce	  microglial	  activation	  in	  the	  brain	  following	  TBI,	  and	  
has	  been	  associated	  with	  improved	  functional	  outcome	  in	  the	  reported	  studies	  (Bye	  et	  al.	  
2007).	  	  It	  has	  also	  been	  found	  to	  reduce	  lesion	  size	  following	  injury	  (Sanchez	  Mejia	  et	  al.	  
2001;	  Bye	  et	  al.	  2007).	  	  	  Although	  minocycline’s	  anti-­‐inflammatory	  effects	  have	  been	  well	  
studied,	  its	  effects	  on	  the	  M1	  and	  M2	  phenotypes	  and	  the	  age-­‐related	  effect	  following	  TBI	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are	  not	  yet	  completely	  understood.	  	  It	  was	  therefore	  the	  goal	  of	  this	  study	  to	  investigate	  the	  
effect	  of	  minocycline	  on	  the	  immune	  response	  and	  reduction	  of	  microglial	  activation	  in	  the	  
brain,	  and	  whether	  M1/M2	  cell	  type	  switching	  is	  involved.	  	  The	  study	  also	  sought	  to	  
compare	  the	  differences	  in	  the	  inflammatory	  response	  between	  young	  and	  aged	  animals	  
with	  minocycline	  treatment.	  	  	  
Based	  on	  prior	  research,	  we	  predicted	  that	  acute	  minocycline	  treatment	  would	  
suppress	  the	  post-­‐injury	  inflammatory	  response	  in	  both	  age	  groups,	  with	  a	  greater	  effect	  in	  
aged	  animals.	  	  We	  also	  expected	  to	  see	  an	  increase	  in	  the	  prevalence	  of	  reparative	  M2	  type	  
cells	  and	  a	  reduction	  in	  M1	  type	  cells	  in	  all	  animals	  given	  minocycline	  treatment.	  	  
	  
TRAUMATIC	  BRAIN	  INJURY	  
Traumatic	  brain	  injury	  (TBI)	  is	  defined	  by	  many	  groups,	  including	  the	  Brain	  Injury	  
Association	  of	  America,	  as	  “an	  alteration	  in	  brain	  function,	  or	  other	  evidence	  of	  brain	  
pathology,	  caused	  by	  an	  external	  force”	  (Menon	  et	  al.	  2010).	  	  In	  humans,	  an	  alteration	  in	  
brain	  function	  is	  manifested	  in	  changes	  in	  level	  of	  consciousness,	  amnesia,	  neurologic	  
deficits	  (weakness,	  paralysis,	  ataxia),	  or	  altered	  mental	  status	  (confusion).	  	  The	  key	  element	  
in	  this	  classification	  is	  the	  term	  “external	  force,”	  which	  separates	  TBI	  from	  other	  types	  of	  
brain	  injury,	  such	  as	  stroke.	  	  There	  are	  different	  types	  of	  external	  forces	  that	  can	  be	  applied	  
to	  the	  brain	  to	  cause	  traumatic	  injury,	  and	  they	  are	  typically	  divided	  into	  two	  categories.	  	  
One	  is	  a	  penetrating	  injury,	  in	  which	  an	  object,	  such	  as	  a	  bullet	  or	  a	  knife,	  enters	  the	  brain.	  	  
The	  other	  is	  a	  non-­‐penetrating,	  or	  closed	  head,	  injury.	  	  This	  type	  of	  injury	  can	  be	  caused	  by	  
either	  contact	  forces	  (like	  an	  object	  striking,	  but	  not	  penetrating,	  the	  head),	  or	  by	  inertial	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forces	  (like	  rapid	  acceleration	  or	  deceleration).	  	  Each	  type	  of	  injury	  can	  further	  be	  described	  
as	  being	  either	  diffuse	  (involving	  large	  portions	  or	  the	  entire	  brain)	  or	  focal	  (involving	  only	  
the	  site	  of	  impact)	  (Greve	  and	  Zink	  2009).	  	  
	  
EPIDEMIOLOGY	  OF	  TBI	  
Traumatic	  brain	  injury	  is	  both	  a	  national	  and	  an	  international	  public	  health	  issue.	  	  
The	  mortality,	  long-­‐term	  disability,	  and	  financial	  burden	  associated	  with	  this	  type	  of	  injury	  
create	  a	  pressing	  problem	  that	  deserves	  to	  be	  addressed.	  	  In	  the	  United	  States,	  TBI	  results	  in	  
over	  1.36	  million	  ER	  visits	  annually,	  of	  which	  about	  35%	  are	  made	  by	  children	  (0	  to	  14	  
years).	  	  TBI	  also	  produces	  275,000	  hospitalizations	  and	  approximately	  52,000	  deaths	  each	  
year,	  with	  the	  highest	  incidence	  rates	  falling	  on	  the	  elderly	  (age	  75	  and	  older)	  (Faul	  et	  al.	  
2010).	  	  Worldwide,	  it	  is	  estimated	  that	  TBI	  affects	  over	  10	  million	  people	  each	  year,	  
although	  this	  is	  often	  considered	  a	  conservative	  assessment	  due	  to	  underreporting	  (Hyder	  
et	  al.	  2007).	  	  	  
In	  the	  United	  States,	  falls	  leads	  the	  list	  of	  causes	  of	  TBI,	  with	  young	  children	  and	  the	  
elderly	  comprising	  the	  majority	  of	  this	  group	  (Faul	  et	  al.	  2010).	  	  Internationally,	  however,	  
motor	  vehicle	  or	  road	  traffic	  injuries	  are	  the	  leading	  cause	  of	  TBI	  (Hyder	  et	  al.	  2007).	  	  In	  both	  
cases,	  motor	  vehicle-­‐related	  injury	  is	  the	  most	  frequent	  cause	  of	  TBI-­‐related	  death.	  
TBI	  also	  places	  financial	  strain	  on	  healthcare	  systems	  and	  individuals	  due	  to	  the	  
associated	  prolonged	  disability	  and	  time	  spent	  on	  rehabilitation	  of	  survivors.	  	  It	  was	  
estimated	  that	  for	  cases	  of	  TBI	  occurring	  in	  the	  US	  in	  the	  year	  2000,	  total	  lifetime	  costs,	  
including	  productivity	  losses,	  amounted	  to	  $60.4	  billion.	  	  Per	  person	  costs	  were	  almost	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$45,000	  (Corrigan	  et	  al.	  2010).	  	  TBI	  is	  a	  problem	  that	  affects	  all	  ages	  and	  socioeconomic	  




Although	  larger	  mammals	  are	  more	  physiologically	  similar	  to	  humans,	  the	  low	  cost,	  
small	  size,	  and	  standardized	  outcome	  measurements	  of	  laboratory	  rodents	  have	  made	  them	  
the	  most	  commonly	  used	  animal	  models	  in	  TBI	  research	  (Xiong	  et	  al.	  2013).	  	  	  To	  model	  
differences	  in	  injury	  response	  between	  young	  and	  aged	  brains,	  two	  rat	  age	  groups	  are	  used	  
in	  experimental	  studies.	  	  Three-­‐month-­‐old	  rats	  and	  20-­‐month-­‐old	  rats	  are	  used	  to	  
correspond	  with	  middle-­‐aged	  and	  elderly	  human	  patients,	  respectively.	  	  	  
Several	  injury	  models	  for	  rodents	  have	  been	  developed,	  each	  with	  its	  own	  
advantages.	  	  One	  of	  the	  most	  common	  is	  the	  controlled	  cortical	  impact	  (CCI)	  injury	  model,	  
which	  uses	  a	  pneumatic	  piston	  to	  inflict	  mainly	  focal	  damage	  upon	  the	  intact	  dura	  via	  a	  
unilateral	  craniotomy	  halfway	  between	  lambda	  and	  bregma.	  	  The	  consequences	  of	  this	  
impact	  include	  cortical	  tissue	  loss	  and	  damage,	  as	  well	  as	  degeneration	  in	  the	  hippocampus	  
and	  thalamus	  (Hall	  et	  al.	  2005).	  	  	  
The	  CCI	  method	  allows	  the	  experimenter	  to	  control	  the	  velocity,	  length	  (time),	  and	  
depth	  of	  impact,	  when	  other	  methods,	  such	  as	  lateral	  fluid	  percussion	  injury	  (LFPI),	  cannot.	  
The	  CCI	  model	  is	  also	  considered	  to	  be	  histopathologically	  similar	  to	  contusion	  injuries	  in	  
humans	  (Morales	  et	  al.	  2005).	  	  While	  this	  model	  of	  injury	  is	  highly	  reproducible	  and	  incurs	  a	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low	  mortality	  rate,	  there	  are	  sometimes	  incidences	  of	  hypoxia	  and	  hypotension	  that	  affect	  





PHASES	  OF	  INJURY	  
	   TBI	  may	  be	  divided	  into	  two	  phases,	  known	  as	  the	  primary	  injury	  and	  the	  secondary	  
injury.	  	  The	  primary	  injury	  is	  the	  initial	  blow	  or	  trauma	  experienced,	  and	  is	  characterized	  by	  
immediate	  tissue	  loss,	  cell	  death,	  and	  mechanical	  disruption	  of	  cells	  and	  cellular	  structures,	  
including	  the	  blood-­‐brain	  barrier	  (BBB).	  	  There	  is	  either	  focal	  or	  diffuse	  damage	  to	  blood	  
vessels,	  axons,	  neurons,	  and	  glia	  (Finnie	  et	  al.	  2013).	  	  Primary	  injury	  is	  usually	  characterized	  
by	  contusions,	  lacerations,	  hemorrhage,	  axonal	  injury/transectioning,	  and	  hypoxia	  (Finnie	  et	  
al.	  2003;	  Das	  et	  al.	  2012).	  	  Mechanoporation	  of	  the	  cell	  membrane	  leads	  to	  an	  influx	  of	  ions,	  
including	  calcium.	  	  The	  disruption	  of	  the	  mitochondrial	  membranes	  halts	  the	  production	  of	  
ATP,	  and	  releases	  certain	  apoptotic	  factors.	  	  Breakdown	  of	  the	  lysosomal	  membrane	  
releases	  degradative	  enzymes	  throughout	  the	  cell.	  	  Some	  cells	  are	  able	  to	  recover	  from	  
these	  insults	  and	  repair	  the	  membranes,	  whereas	  others	  are	  forced	  to	  die	  (Greve	  and	  Zink	  
2009).	  	  After	  the	  traumatic	  event	  has	  occurred,	  cells	  are	  left	  vulnerable	  to	  a	  secondary	  
injury,	  which	  may	  begin	  within	  minutes	  to	  hours	  and	  persist	  for	  days	  to	  months	  (Das	  et	  al.	  
2012).	  	  While	  the	  primary	  injury	  is	  untreatable	  (although	  sometimes	  preventable),	  there	  is	  a	  
window	  of	  opportunity	  for	  treatment	  during	  the	  secondary	  insult,	  to	  improve	  survival	  and	  
outcome.	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   The	  secondary	  injury	  can	  be	  characterized	  by	  further	  breakdown	  of	  the	  BBB,	  
ischemia,	  edema,	  hematomas,	  elevated	  intracranial	  pressure,	  and	  infection	  (in	  a	  penetrating	  
injury).	  	  The	  secondary	  injury	  is	  multi-­‐faceted,	  but	  mostly	  occurs	  in	  response	  to	  the	  
metabolic	  disruption	  caused	  by	  the	  primary	  insult.	  	  It	  is	  now	  well-­‐documented	  that	  trauma	  
causes	  excitotoxicity	  in	  the	  brain,	  due	  to	  a	  large	  and	  uncontrolled	  release	  of	  
neurotransmitters	  from	  cells,	  which	  contributes	  to	  the	  huge	  ionic	  fluxes	  seen	  after	  injury	  
(Giza	  and	  Hovda	  2001).	  	  The	  large	  influx	  of	  calcium	  observed	  is	  detrimental	  for	  several	  
reasons,	  including	  its	  impairment	  of	  mitochondrial	  oxidative	  metabolism	  and	  involvement	  in	  
cell	  death	  pathways	  (Giza	  and	  Hovda	  2001).	  	  There	  is	  also	  a	  large	  efflux	  of	  potassium	  from	  
cells,	  which	  causes	  the	  release	  of	  more	  excitatory	  amino	  acids,	  further	  contributing	  to	  the	  
excitotoxicity.	  	  Ultimately,	  the	  dramatic	  changes	  in	  ion	  concentrations	  lead	  to	  depression	  of	  
neuronal	  activity	  (Katayama	  1990).	  	  There	  is	  also	  evidence	  that	  increased	  metabolism	  after	  
injury	  enhances	  the	  production	  of	  oxygen	  radicals	  (Kontos	  and	  Povlishock,	  1986).	  	  These	  
free	  radicals	  then	  initiate	  cascades	  including	  lipid	  peroxidation,	  leading	  to	  loss	  of	  vascular	  
integrity	  (disruption	  of	  the	  BBB)	  (Smith	  et	  al.	  1994).	  
	   The	  damage	  caused	  by	  excitotoxicity	  after	  trauma	  and	  neuronal	  impairment	  is	  
exacerbated	  when	  damaged	  cells	  also	  undergo	  a	  large	  influx	  of	  calcium	  and	  sodium,	  and	  an	  
efflux	  of	  potassium.	  	  The	  increase	  in	  intracellular	  calcium	  then	  stimulates	  the	  release	  of	  
internal	  stores	  of	  calcium	  (calcium-­‐induced	  calcium-­‐release),	  causing	  a	  further	  rise	  in	  
calcium	  concentration	  inside	  the	  cell.	  	  This	  calcium	  is	  responsible	  for	  the	  activation	  of	  
certain	  calcium-­‐dependent	  proteases	  inside	  the	  cells,	  such	  as	  calpains	  and	  caspases.	  	  These	  
proteases,	  once	  activated,	  lead	  to	  the	  break	  down	  of	  the	  cytoarchitecture	  of	  the	  cell,	  and	  
thus	  contribute	  to	  cell	  death	  (Greve	  and	  Zink	  2009;	  Raghupathi	  2004).	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A	  large	  contributor	  to	  the	  secondary	  injury	  is	  the	  inflammatory	  response,	  mediated	  
principally	  by	  microglia	  in	  the	  brain.	  	  However,	  breakdown	  of	  the	  BBB	  following	  TBI	  causes	  
increased	  permeability	  of	  the	  CNS	  to	  infiltrating	  inflammatory	  cells	  and	  signaling	  molecules	  
(Das	  et	  al.	  2012).	  	  Microglia,	  as	  well	  as	  infiltrating	  leukocytes,	  release	  pro-­‐inflammatory	  
cytokines	  like	  TFN-­‐α	  and	  IL-­‐1β.	  	  These	  cells	  also	  remove	  inhibitory	  tissue	  debris	  and	  secrete	  
growth-­‐promoting	  factors,	  involved	  in	  regeneration	  of	  cells	  and	  tissue.	  	  
The	  cytokine	  levels	  rise	  within	  minutes	  of	  injury	  and	  can	  peak	  within	  hours,	  so	  it	  is	  
necessary	  to	  suppress	  the	  acute	  response	  in	  order	  to	  prevent	  or	  reduce	  secondary	  damage.	  	  
The	  cytokine	  IL-­‐1	  β,	  for	  example,	  reaches	  maximal	  levels	  in	  the	  hippocampus	  one	  to	  two	  
hours	  after	  injury	  (Dalgard	  et	  al.	  2012).	  	  Because	  the	  secondary	  injury	  may	  in	  many	  cases	  be	  
preventable	  it	  is	  important	  to	  investigate	  possible	  treatments	  and	  therapies	  to	  minimize	  
damage	  caused	  by	  this	  phase.	  
	  
AGING	  AND	  TBI	  RESPONSE	  AND	  RECOVERY	  
While	  advanced	  age	  is	  known	  to	  correlate	  with	  poor	  outcome	  following	  TBI,	  the	  
reasons	  for	  the	  phenomenon	  are	  still	  not	  completely	  understood.	  	  Often,	  the	  age	  of	  the	  
patient	  determines	  survival	  after	  TBI,	  as	  well	  as	  the	  severity	  of	  the	  injury	  and	  degree	  of	  
recovery.	  	  Possible	  causes	  for	  this	  strong	  association	  include	  an	  increased	  inflammatory	  
response	  in	  aged	  individuals,	  more	  severe	  secondary	  injuries,	  and	  an	  inability	  to	  
compensate	  for	  neurological	  deficits	  (e.g.	  decreased	  neuroplasticity).	  	  Generally,	  the	  
inflammatory	  response	  is	  less	  coordinated	  and	  therefore	  not	  as	  efficient	  at	  responding	  to	  an	  
insult	  as	  in	  a	  younger	  individual	  (Godbout	  et	  al.	  2005).	  	  In	  aged	  animal	  models	  of	  TBI,	  we	  see	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delayed	  recruitment	  of	  monocytes,	  less	  chemotactic	  activity,	  decreased	  ability	  to	  regulate	  
microglial	  proliferation,	  decreased	  cytokine	  production,	  and	  reduced	  phagocytosis	  (Conde	  
and	  Streit	  2006;	  Stout	  and	  Suttles	  2005).	  	  Also,	  there	  is	  a	  decrease	  in	  the	  production	  of	  
certain	  growth	  factors,	  like	  FGF-­‐2	  and	  VEGF,	  leading	  to	  impaired	  recovery	  after	  injury	  (Stout	  
and	  Suttles	  2005).	  	  
The	  idea	  of	  “immunosenescence,”	  or	  changes	  to	  the	  immune	  system	  caused	  by	  
aging,	  is	  continuing	  to	  be	  explored	  in	  research.	  	  Studies	  have	  shown	  that	  with	  age	  there	  is	  an	  
increased	  presence	  of	  dystrophic	  microglia,	  or	  microglia	  with	  abnormal	  cytoplasmic	  
structures	  and	  morphology,	  in	  the	  brain	  (Streit	  et	  al.	  2004).	  	  This,	  along	  with	  the	  fact	  that	  
microglial	  expression	  of	  MHC	  class	  II	  (a	  marker	  of	  activation)	  increases	  with	  age,	  seems	  to	  
indicate	  that	  the	  normal	  aged	  brain	  is	  “primed”	  for	  an	  exaggerated	  response	  after	  injury	  
(Godbout	  et	  al.	  2005).	  	  	  
A	  comparison	  of	  healthy	  rat	  cortical	  tissue	  by	  age	  showed	  that	  systemic	  microglial	  
activation	  increases	  with	  age,	  thought	  to	  be	  due	  to	  minor	  insults	  to	  the	  CNS	  incurred	  over	  
time	  (Vaughan	  et	  al.	  1974).	  In	  a	  recent	  TBI	  study	  in	  mice,	  it	  was	  found	  that	  aged	  subjects	  
had	  a	  higher	  mortality	  rate	  and	  worse	  neurologic	  outcomes	  that	  did	  not	  correlate	  with	  
histopathological	  damage	  (Timaru-­‐Kast	  et	  al.	  2012).	  	  	  Examination	  of	  certain	  inflammatory	  
markers,	  including	  iNOS	  and	  IL1-­‐β,	  revealed	  that	  aged	  mice	  already	  had	  higher	  basal	  levels	  
of	  these	  cytokines	  in	  the	  CNS,	  which	  may	  have	  lead	  to	  an	  exaggerated	  inflammatory	  
response	  after	  injury.	  	  In	  comparing	  the	  responses	  of	  young	  and	  aged	  mice,	  it	  was	  found	  
that	  old	  animals	  exhibited	  early	  and	  high	  increases	  in	  the	  markers	  IL-­‐1β	  and	  TNF-­‐α,	  while	  
young	  animals	  had	  delayed	  increases	  (Timaru-­‐Kast	  et	  al.	  2012).	  	  This	  strong,	  early	  expression	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in	  aged	  animals	  could	  exacerbate	  the	  secondary	  damage	  and	  cause	  increased	  neuronal	  cell	  
death.	  	  
	   Other	  studies	  comparing	  aged	  and	  young	  rodents	  have	  found	  similar	  correlations.	  	  
Increased	  age	  has	  often	  been	  associated	  with	  higher	  numbers	  of	  activated	  microglia	  in	  
specific	  brain	  regions,	  including	  the	  hippocampus	  (Sandhir	  et	  al.	  2008).	  	  The	  hippocampus,	  
being	  one	  of	  the	  few	  brain	  regions	  that	  continue	  to	  produce	  new	  neurons	  even	  in	  
adulthood,	  is	  particularly	  vulnerable	  to	  TBI	  damage.	  	  Increased	  glial	  activation	  may	  affect	  
repair	  and	  recovery	  in	  these	  regions,	  and	  lead	  to	  worse	  outcomes	  in	  aged	  brains.	  
	   	  After	  young	  children,	  incidences	  of	  TBI	  peak	  again	  in	  the	  elderly,	  and	  adults	  age	  75	  
and	  older	  have	  the	  highest	  rates	  of	  TBI-­‐associated	  hospitalization	  and	  death	  (Faul	  et	  al.	  
2010).	  	  In	  order	  to	  address	  this	  significantly	  affected	  population,	  the	  differences	  in	  
inflammatory	  responses	  between	  young	  and	  aged	  brains	  must	  be	  further	  investigated,	  
particularly	  in	  regard	  to	  the	  presence	  of	  specific	  microglial	  subpopulations	  (discussed	  
further	  in	  the	  following	  sections).	  	  Additionally,	  the	  impact	  of	  an	  anti-­‐inflammatory	  drug,	  
like	  minocycline,	  on	  aged	  animals	  following	  TBI	  has	  not	  been	  well	  examined	  and	  requires	  
further	  exploration.	  
	  
IMMUNE	  RESPONSE	  IN	  THE	  CNS	  
First	  described	  in	  detail	  by	  Del	  Rio-­‐Hortega	  in	  1932,	  microglia	  are	  now	  known	  to	  
constitute	  about	  10-­‐20%	  of	  the	  total	  CNS	  cell	  population.	  	  In	  contrast	  to	  the	  other	  glial	  cells	  
of	  the	  CNS	  (i.e.	  astroctyes	  and	  oligodendrocytes),	  which	  originate	  from	  the	  neuroectoderm,	  
microglia	  have	  a	  monocyte/macrophage	  lineage	  and	  originate	  from	  the	  mesoderm.	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Circulating	  monocytes	  invade	  the	  developing	  brain	  during	  early	  developmental	  stages	  and	  
transform	  into	  microglial	  cells.	  	  Microglia	  are	  best	  known	  as	  the	  resident	  immune	  cells	  of	  
the	  central	  nervous	  system	  (CNS),	  meaning	  that	  they	  are	  always	  present	  and	  monitoring	  the	  
environment	  for	  pathogens	  via	  pattern	  recognition	  receptors	  (PRRs)	  (Block	  et	  al.	  2007).	  	  In	  
this	  way,	  they	  play	  an	  important	  role	  in	  maintaining	  normal	  tissue	  homeostasis.	  	  In	  addition,	  
microglia	  are	  known	  to	  be	  involved	  in	  synaptic	  regulation,	  neuronal	  cell	  death,	  and	  neuronal	  
differentiation	  (Loane	  and	  Byrnes	  2010).	  
At	  rest,	  microglia	  have	  a	  “ramified”	  morphology	  as	  they	  send	  out	  long,	  branched	  
processes	  that	  survey	  the	  immediate	  surroundings,	  reacting	  to	  chemical	  as	  well	  as	  physical	  
signals.	  	  Resting	  microglia	  in	  this	  ramified	  state	  present	  a	  relatively	  continuous	  population	  in	  
the	  adult	  brain,	  and	  exhibit	  a	  slow	  turnover	  (little	  proliferation	  or	  recruitment)	  (Ohsawa	  and	  
Kohsaka	  2009).	  	  Cells	  in	  this	  state	  are	  characterized	  by	  constitutive	  expression	  of	  cell	  surface	  
markers	  like	  CD11b	  and	  Iba1,	  as	  well	  as	  a	  reduced	  level	  of	  major	  histocompatibility	  complex	  
(MHC)	  markers	  and	  phagocytic	  markers	  (ED1)	  (Ohsawa	  and	  Kohsaka	  2009).	  	  	  
When	  stimulated,	  microglia	  take	  on	  a	  more	  “amoeboid”	  shape	  and	  are	  appear	  more	  
hypertrophied	  with	  shorter	  processes.	  	  These	  cells	  up-­‐regulate	  certain	  cell-­‐surface	  
molecules,	  including	  MHC	  molecules,	  CD14,	  Iba1	  and	  chemokine	  receptors	  (Block	  et	  al.	  
2007).	  	  Causes	  of	  microglial	  activation	  are	  varied,	  but	  include	  environmental	  toxins	  as	  well	  
as	  neuronal	  damage	  (Block	  et	  al.	  2007).	  	  After	  TBI,	  there	  is	  often	  disruption	  of	  the	  BBB,	  
leading	  to	  infiltration	  of	  monocytes	  and	  macrophages	  from	  the	  blood	  into	  the	  CNS.	  	  These	  
cells	  are	  indistinguishable	  from	  resident	  microglia	  that	  have	  been	  activated	  after	  injury.	  
Microglia	  provide	  the	  first	  line	  of	  defense	  against	  potentially	  harmful	  microbes	  or	  
molecules	  and	  thus	  comprise	  the	  innate	  immune	  system	  of	  the	  CNS.	  	  This	  innate	  response,	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being	  immediate	  and	  non-­‐specific,	  contrasts	  with	  the	  subsequent	  adaptive	  response,	  which	  
is	  delayed	  but	  specific	  to	  the	  type	  of	  damage.	  	  Microglia	  phagocytize	  cellular	  debris	  as	  well	  
as	  pathogens,	  and	  secrete	  cytokines	  that	  activate	  more	  cells	  and	  draw	  other	  types	  of	  
immune	  cells	  to	  the	  area	  (Martinez	  et	  al.	  2008).	  	  The	  PRRs	  on	  their	  surface,	  such	  as	  toll-­‐like	  
receptors	  (TLRs),	  interact	  with	  various	  pathogen-­‐associated	  molecular	  patterns	  (PAMPs)	  or,	  
as	  in	  the	  case	  of	  most	  TBIs,	  damage-­‐associated	  molecular	  patterns	  (DAMPs)	  in	  the	  
environment	  (Colton	  2009).	  	  These	  interactions	  start	  a	  cascade	  of	  events	  within	  the	  cell,	  
ultimately	  triggering	  the	  induction	  of	  certain	  genes	  that	  effect	  the	  expression	  of	  
inflammatory	  cytokines,	  such	  as	  TNF-­‐α	  and	  IL-­‐1β	  (Colton	  2009).	  	  	  
It	  can	  also	  be	  harmful	  to	  the	  host	  when	  necrotic	  and	  apoptotic	  pathways	  are	  strongly	  
expressed,	  or	  the	  reaction	  is	  prolonged.	  	  Chronic	  activation	  can	  be	  detrimental	  due	  to	  the	  
continuous	  release	  of	  potentially	  cytotoxic	  molecules,	  such	  as	  pro-­‐inflammatory	  cytokines,	  
ROS	  and	  their	  intermediates,	  proteinases,	  and	  complement	  proteins.	  	  However,	  microglia	  
are	  also	  involved	  in	  the	  wound	  healing	  process	  after	  injury,	  and	  release	  growth	  factors,	  such	  
as	  TGF-­‐β,	  necessary	  for	  neuron	  repair	  and	  vascular	  regeneration	  (Vereyken	  et	  al.	  2011).	  	  In	  
addition,	  studies	  showing	  the	  detrimental	  effects	  of	  the	  impaired	  function	  of	  microglia	  or	  
depletion	  of	  the	  cell	  type	  indicate	  the	  necessity	  of	  the	  microglial	  response	  to	  recovery	  
(Lalancette-­‐Hebert	  et	  al.	  2007;	  Loane	  and	  Byrnes	  2010).	  
	  
TYPES	  OF	  MICROGLIA/MACROPHAGES	  
This	  dual	  role	  of	  macrophages	  in	  the	  inflammatory	  response	  has	  led	  to	  the	  classification	  
system	  used	  today	  to	  differentiate	  the	  two	  major	  phenotypes	  of	  microglial	  activation.	  	  The	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first	  are	  known	  as	  “classically	  activated”	  microglia,	  or	  simply	  M1,	  meaning	  that	  the	  cell	  
releases	  primarily	  pro-­‐inflammatory	  cytokines.	  	  The	  second	  are	  termed	  “alternatively	  
activated”,	  or	  M2,	  meaning	  that	  the	  cell	  secretes	  primarily	  anti-­‐inflammatory	  cytokines.	  	  It	  
has	  been	  determined	  that	  in	  the	  intact	  CNS,	  microglia	  exhibit	  an	  M2	  phenotype	  (Jiang	  et	  al.	  
2012).	  	  In	  the	  case	  of	  injury,	  however,	  the	  specific	  lesion	  microenvironment	  determines	  the	  
activation	  of	  the	  microglia	  (Vereyken	  et	  al.	  2011).	  	  These	  M1/M2	  designations	  have	  been	  
further	  clarified	  through	  extensive	  studies,	  and	  a	  more	  detailed	  explanation	  of	  differences	  
between	  the	  two	  groups	  follows.	  	  	  
M1	  (pro-­‐inflammatory)	  cells	  are	  inducible	  by	  the	  introduction	  of	  inflammatory	  cytokines,	  
such	  as	  IFN-­‐ϒ,	  as	  well	  as	  LPS	  (lipopolysaccharide).	  	  They	  are	  themselves	  characterized	  by	  
high	  expression	  of	  inflammatory	  cytokines,	  including	  IL-­‐12,	  IL-­‐23,	  TNF-­‐α,	  and	  IL1-­‐β,	  and	  
chemokines,	  like	  CCL15/Hcc-­‐2.	  	  M1	  cells	  exhibit	  enhanced	  endocytic	  functions,	  as	  well	  as	  an	  
increased	  ability	  to	  destroy	  intracellular	  pathogens.	  	  They	  accomplish	  this	  via	  several	  
different	  mechanisms,	  including	  restriction	  of	  nutrients	  (e.g.	  iron),	  acidification	  of	  
phagosomes,	  and	  synthesis	  of	  reactive	  oxygen	  species	  (ROS).	  	  M1	  macrophages	  also	  express	  
inducible	  nitric	  oxide	  synthase	  (iNOS),	  which	  skews	  the	  metabolism	  of	  arginine	  toward	  
production	  of	  nitric	  oxide	  (NO)	  (Martinez	  et	  al.	  2008).	  	  These	  microglia/macrophages	  are	  
necessary	  in	  protecting	  the	  host	  against	  exogenous	  pathogens	  and	  debris	  left	  by	  injury,	  but	  
can	  also	  cause	  increased	  tissue	  damage	  by	  attacking	  healthy	  host	  cells.	  	  	  M1	  cells	  also	  
exhibit	  higher	  levels	  of	  phagocytic	  activity	  involving	  myelin	  and	  neuronal	  fragments	  
(Vereyken	  et	  al.	  2011).	  
M2	  anti-­‐inflammatory	  microglia	  may	  be	  induced	  by	  factors	  such	  as	  IL-­‐4,	  IL-­‐13,	  IL-­‐10,	  and	  
TGF-­‐β	  (Stein	  et	  al.	  1992;).	  	  These	  cells	  then	  express	  similar	  anti-­‐inflammatory	  molecules,	  in	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addition	  to	  extracellular	  matrix	  molecules	  (e.g.	  fibronectin),	  scavenger	  receptors	  (e.g.	  
CD163),	  and	  glucocorticoids.	  	  	  Specifically,	  IL-­‐10	  is	  known	  to	  inhibit	  production	  of	  pro-­‐
inflammatory	  cytokines,	  TGF-­‐β	  controls	  microglial	  activation,	  cytokine	  production,	  and	  
chemotaxis.	  	  Glucocorticoids	  bind	  receptors	  in	  the	  nucleus	  and	  inhibit	  the	  production	  of	  pro-­‐
inflammatory	  cytokines,	  as	  well	  as	  the	  enzymes	  that	  produce/mediate	  them,	  and	  down-­‐
regulate	  the	  genes	  that	  are	  usually	  up-­‐regulated	  by	  IFN-­‐ϒ.	  	  They	  also	  enhance	  expression	  of	  
anti-­‐inflammatory	  cytokines	  (Martinez	  et	  al.	  2008).	  	  M2	  cells	  are	  mainly	  involved	  in	  tissue	  
repair	  mechanisms	  and	  are	  believed	  to	  have	  a	  neuro-­‐protective	  role	  (Zhang	  et	  al.	  2012).	  	  M2	  
microglia/macrophages	  express	  high	  levels	  of	  arginase	  I	  (ARGI),	  which	  competes	  with	  iNOS	  
for	  use	  of	  arginine	  as	  a	  substrate.	  	  Arginse	  I	  produces	  proline	  and	  polyamines	  that	  promote	  
cell	  growth,	  collagen	  formation,	  and	  tissue	  repair	  (Martinez	  et	  al.	  2008).	  	  M2	  cells	  also	  
promote	  angiogenesis	  by	  producing	  necessary	  growth	  factors,	  such	  as	  PDGF,	  VEGF,	  and	  FGF	  
(Vereyken	  et	  al.	  2011).	  	  M2	  cells	  are	  also	  known	  to	  secrete	  matrix	  metalloprotease-­‐1	  (MMP-­‐
1)	  and	  MMP-­‐12,	  which	  are	  involved	  in	  substrate	  remodeling,	  and	  downregulate	  MMP-­‐9,	  
which	  has	  been	  implicated	  in	  regeneration	  failure	  after	  CNS	  injury	  (Busch	  et	  al.	  2011).	  	  	  
The	  term	  M2	  is	  now	  regarded	  as	  a	  general	  name	  for	  a	  continuum	  of	  anti-­‐inflammatory	  
cell	  types,	  which	  are	  functionally	  and	  phenotypically	  related.	  	  Subsets	  have	  been	  named	  
with	  various	  terminologies	  (e.g.	  M2a	  and	  M2b),	  which	  differentiate	  the	  cell	  types	  by	  
assorted	  characteristics,	  such	  as	  how	  they	  are	  induced	  and	  whether	  they	  express	  certain	  
enzymes.	  	  
In	  a	  study	  by	  Dheen	  and	  associates	  (2007),	  neurogenesis	  in	  the	  adult	  hippocampus	  was	  
examined.	  	  The	  hippocampus	  is	  uniquely	  appropriate	  for	  this	  type	  of	  study	  due	  to	  its	  
permanent	  population	  of	  neural	  stem	  cells,	  which	  allows	  it	  to	  continually	  produce	  new	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neurons	  even	  in	  adulthood.	  	  In	  this	  study,	  neurogenesis,	  in	  vitro,	  was	  inhibited	  when	  the	  
NSCs	  were	  exposed	  to	  activated	  microglia.	  	  This	  suggests	  that	  the	  pro-­‐inflammatory	  factors	  
released	  by	  M1	  cells	  could	  contribute	  to	  blocking	  of	  neurogenesis.	  	  Accordingly,	  treatment	  
with	  NSAIDs	  restored	  neurogenesis	  in	  the	  hippocampus.	  	  	  
Some	  research	  has	  been	  done	  to	  explore	  the	  relationship	  between	  the	  two	  types	  of	  
macrophages.	  	  One	  such	  study	  saw	  that	  the	  introduction	  of	  Multipotent	  Adult	  Progenitor	  
Cell	  (MAPC)	  -­‐secreted	  factors	  induced	  a	  shift	  from	  M1	  to	  M2,	  which	  enhanced	  regrowth	  
after	  a	  spinal	  cord	  injury	  by	  minimizing	  axonal	  dieback	  at	  the	  injury	  site	  (Busch	  et	  al.	  2011).	  	  
Axonal	  dieback	  is	  thought	  to	  be	  mediated	  by	  MMP-­‐9,	  a	  protease	  that	  is	  upregulated	  in	  M1	  
cells.	  	  	  
The	  idea	  of	  a	  dual	  role	  of	  microglia	  in	  injury	  and	  repair	  has	  led	  to	  an	  interest	  in	  
experimenting	  with	  the	  balance	  between	  M1	  and	  M2	  cells.	  	  Specifically,	  whether	  
suppressing	  the	  pro-­‐inflammatory	  cells	  and	  activating	  the	  anti-­‐inflammatory	  cells	  leads	  to	  
better	  recovery	  after	  injury.	  	  	  In	  a	  study	  by	  Jiang	  and	  colleagues	  (2012),	  Substance	  P	  (SP)	  was	  
used	  as	  an	  inducer	  of	  the	  M2	  phenotype	  in	  macrophages	  after	  spinal	  cord	  injury.	  	  It	  was	  
found	  that	  with	  SP	  treatment	  the	  area	  around	  the	  injury	  site	  was	  induced	  toward	  a	  more	  
anti-­‐inflammatory	  state,	  by	  way	  of	  up-­‐regulating	  IL-­‐10	  and	  arginase-­‐1	  expression	  and	  down-­‐
regulating	  iNOS,	  IL-­‐6,	  and	  TNF-­‐α	  expression	  by	  the	  microglia	  in	  the	  CNS.	  	  These	  effects	  of	  the	  
drug	  on	  M1/M2	  phenotype	  modulation	  were	  noticed	  at	  one-­‐day-­‐post-­‐injury.	  	  Not	  only	  was	  
functional	  recovery	  greater	  in	  the	  SP	  treatment	  groups,	  as	  compared	  to	  controls,	  but	  
neuronal	  processes	  and	  vasculature	  were	  seen	  in	  the	  lesion	  sites	  as	  well.	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MINOCYCLINE	  AS	  A	  TREATMENT	  
Minocycline	  is	  a	  commonly	  used	  tetracycline-­‐derived	  antibiotic.	  	  Already	  FDA-­‐approved,	  
it	  has	  been	  used	  for	  decades	  to	  effectively	  treat	  infections	  ranging	  from	  periodontitis	  to	  
acne	  vulgaris.	  	  Side	  effects	  are	  usually	  mild,	  and	  the	  symptoms	  most	  commonly	  reported	  by	  
people	  taking	  the	  drug	  have	  been	  gastrointestinal	  issues	  and	  dizziness	  (Elewa	  et	  al.	  2006).	  	  
In	  addition	  to	  its	  anti-­‐microbial	  properties,	  minocycline	  also	  has	  also	  been	  shown	  to	  exert	  
anti-­‐inflammatory	  effects,	  making	  it	  a	  strong	  candidate	  for	  therapy	  during	  the	  secondary	  
injury	  following	  TBI.	  
Minocycline	  is	  lipid-­‐soluble	  and	  able	  to	  cross	  the	  blood-­‐brain	  barrier	  (BBB),	  meaning	  it	  
can	  be	  administered	  orally,	  intravenously	  (I.V.),	  or	  even	  intra-­‐peritoneally	  (I.P.).	  	  Other	  
advantages	  of	  minocycline	  treatment	  include	  its	  ability	  to	  exert	  its	  protective	  effect	  for	  a	  
relatively	  long	  time	  (>3	  hours	  after	  injection).	  	  It	  is	  also	  able	  to	  inhibit	  several	  mechanisms	  of	  
secondary	  injury,	  as	  opposed	  to	  very	  specific	  treatments	  (calcium	  channel	  blockers,	  
glutamate	  antagonists)	  that	  leave	  other	  lines	  of	  damage	  open	  (Wells	  et	  al.	  2003).	  
It	  has	  been	  repeatedly	  demonstrated	  that	  minocycline	  has	  anti-­‐inflammatory	  as	  well	  as	  
neuroprotective	  properties,	  in	  a	  variety	  of	  experimental	  models.	  	  In	  a	  study	  by	  Ng	  and	  
associates	  (2012),	  mice	  in	  a	  closed	  head	  injury	  model	  treated	  with	  minocycline	  had	  
significantly	  reduced	  activation	  and	  recruitment	  of	  microglia/macrophages	  to	  both	  the	  
hippocampus	  and	  injury	  site.	  	  This	  finding	  was	  also	  associated	  with	  better	  neurological	  
outcome.	  	  Another	  murine	  study	  employing	  a	  CCI	  injury	  found	  that	  minocycline	  treatment	  
resulted	  in	  decreased	  lesion	  volume,	  improved	  neurological	  function,	  and	  reduced	  
production	  of	  an	  inflammatory	  cytokine,	  IL-­‐1β	  (Bye	  et	  al.	  2007).	  	  	  The	  drug	  has	  also	  been	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associated	  with	  suppression	  of	  microgliosis,	  apoptosis,	  free	  radical	  formation,	  and	  
peripheral	  inflammation	  (Hewlett	  et	  al.	  2006).	  
The	  anti-­‐inflammatory	  effects	  of	  minocycline	  are	  numerous.	  	  In	  general,	  the	  drug	  
inhibits	  migration	  and	  infiltration	  of	  inflammatory	  cells,	  as	  well	  as	  suppresses	  ROS	  
formation.	  	  It	  blocks	  enzymes	  that	  contribute	  to	  inflammation,	  such	  as	  iNOS	  and	  caspase-­‐1	  
(Sanchez	  Mejia	  et	  al.	  2001).	  	  Caspase-­‐1	  has	  been	  implicated	  in	  cellular	  apoptotic	  
mechanisms	  that	  are	  activated	  following	  TBI.	  	  It	  also	  inhibits	  the	  production	  of	  ROS	  and	  
expression	  of	  pro-­‐inflammatory	  cytokines,	  like	  IL1-­‐β,	  by	  microglia	  (Dheen	  et	  al.	  2007).	  	  
Minocycline	  also	  suppresses	  apoptosis	  by	  inhibiting	  the	  release	  of	  cytochrome	  c	  from	  
mitochondria	  and	  inducing	  the	  up-­‐regulation	  of	  Bcl-­‐2	  (Matsukawa	  et	  al.	  2005).	  	  The	  drug,	  
like	  all	  tetracyclines,	  also	  inhibits	  matrix	  metallo-­‐proteases	  (MMPs),	  which	  are	  frequently	  
associated	  with	  the	  degeneration	  of	  extracellular	  proteins.	  	  MMPs	  are	  enzymes	  that	  are	  key	  
in	  the	  process	  of	  leukocyte	  infiltration	  because	  they	  cleave	  tissue	  components	  like	  
fibronectin	  and	  collagen	  (Parks	  et	  al.	  2004).	  	  	  
	   This	  research	  suggests	  that	  minocycline	  could	  suppress	  inflammation	  and	  promote	  
repair	  in	  the	  injured	  brain	  by	  supporting	  a	  switch	  from	  the	  M1	  to	  M2	  microglial	  phenotype.	  	  
Therefore,	  the	  current	  study	  will	  investigate	  the	  effect	  of	  minocycline	  treatments	  on	  the	  
acute	  inflammatory	  response	  following	  CCI	  injury.	  	  The	  study	  will	  also	  compare	  drug’s	  effect	  
on	  young	  animals	  (3-­‐month-­‐old)	  to	  aged	  animals	  (20-­‐month-­‐old),	  which	  are	  known	  to	  have	  
elevated	  microglial	  activation	  and	  pro-­‐inflammatory	  cytokine	  production	  after	  injury.	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METHODS	  
SUBJECTS	  
The	  experimental	  procedures	  used	  in	  this	  study	  followed	  all	  NIH	  guidelines	  and	  were	  
approved	  by	  the	  Institutional	  Animal	  Care	  and	  Use	  Committee	  at	  Virginia	  Commonwealth	  
University.	  	  Three-­‐month-­‐old	  (approximately	  300g	  each)	  and	  20-­‐month-­‐old	  (approximately	  
450g	  each)	  Fisher	  344	  rats	  were	  used	  in	  this	  study.	  	  All	  animals	  were	  housed	  under	  normal	  
conditions	  (temperature	  of	  20-­‐22°C	  with	  a	  12-­‐hour	  light/dark	  cycle),	  and	  were	  provided	  
food	  and	  water	  ad	  libitum.	  	  The	  young	  rats	  were	  housed	  in	  pairs,	  while	  the	  aged	  rats	  were	  
housed	  individually.	  	  The	  current	  study	  used	  tissue	  obtained	  from	  32	  animals,	  consisting	  of	  
18	  young	  rats	  and	  14	  aged	  rats,	  to	  examine	  the	  effects	  of	  minocycline	  treatment	  on	  the	  
injury-­‐induced	  inflammatory	  response.	  	  	  The	  animals	  were	  divided	  into	  sham,	  vehicle,	  and	  
two	  minocycline	  treatment	  groups	  (Table	  1).	  	  	  
	  
TABLE	  2-­‐1:	  ANIMAL	  GROUPING	  	  
	  
	   Controlled	  Cortical	  Impact	  (CCI)	  Injury	  
	   Young	  (3M)	   Aged	  (20M)	  
Sham	   3	   2	  
Vehicle	   5	   4	  
Minocycline	  Treatment	  
Group	  1	   6	   4	  
Minocycline	  Treatment	  
Group	  2	   4	   4	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SURGICAL	  PREPARATION	  AND	  PROCEDURE	  
Fifteen	  of	  the	  young	  animals	  and	  twelve	  of	  the	  aged	  animals	  used	  in	  this	  study	  endured	  
CCI	  injury.	  	  The	  rest	  of	  the	  animals	  were	  shams	  and	  underwent	  the	  same	  procedures	  
without	  injury.	  	  All	  surgeries	  were	  carried	  out	  in	  an	  aseptic	  environment	  and	  used	  
autoclave-­‐sterilized	  equipment,	  following	  protocol	  guidelines.	  	  Anesthetization	  before	  
surgery	  was	  achieved	  with	  5%	  isoflurane	  delivered	  in	  a	  Plexiglas	  chamber.	  	  The	  subject	  was	  
then	  removed	  from	  the	  chamber	  and	  kept	  on	  continuous	  2.5%	  isoflurane/gas	  (30%	  oxygen	  
and	  70%	  nitrogen)	  ventilation	  via	  a	  nose	  cone.	  	  The	  surgical	  area,	  shaved	  of	  fur,	  was	  
cleansed	  with	  Betadine,	  and	  Puralube	  ointment	  was	  placed	  around	  the	  eyes	  to	  prevent	  
drying	  out.	  	  After	  arranging	  the	  animal	  on	  the	  stereotaxic	  frame,	  over	  a	  heating	  pad.	  	  A	  
midline	  incision	  was	  made	  in	  the	  scalp	  and	  hemostats	  were	  used	  to	  pull	  away	  the	  
surrounding	  skin	  and	  connective	  tissue	  to	  expose	  the	  skull.	  	  A	  trephine	  and	  a	  Dremel	  drill	  
were	  used	  to	  make	  a	  4.9	  mm	  craniotomy,	  without	  piercing	  the	  dura,	  at	  a	  position	  on	  the	  left	  
parietal	  bone	  midway	  between	  lambda	  and	  bregma.	  	  The	  craniotomy	  was	  carefully	  cleared	  
of	  bone	  fragments	  before	  continuing.	  
	  
CONTROLLED	  CORTICAL	  IMPACT	  (CCI)	  INJURY	  
The	  injury	  model	  used	  for	  this	  study	  was	  the	  controlled	  cortical	  impact	  (CCI)	  model.	  	  
After	  the	  craniotomy,	  the	  rat	  was	  disconnected	  from	  anesthesia.	  	  The	  subject	  was	  then	  
placed	  in	  the	  CCI	  injury	  device	  (Figure	  1)	  and	  the	  device	  was	  calibrated	  by	  lowering	  the	  3mm	  
steel	  impactor	  to	  the	  surface	  of	  the	  brain	  exposed	  by	  the	  craniotomy.	  	  This	  step	  ensured	  
that	  the	  correct	  depth	  would	  be	  achieved	  during	  injury	  and	  that	  the	  dura	  would	  not	  be	  
pierced.	  	  The	  subject	  was	  kept	  in	  place	  until	  it	  exhibited	  a	  tail	  reflex,	  at	  which	  point	  the	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injury	  was	  delivered.	  	  Injury	  consisted	  of	  a	  2.3	  mm	  depression	  of	  the	  dura	  by	  the	  steel	  
impactor	  at	  a	  velocity	  of	  4	  m/s	  and	  a	  dwell	  time	  of	  50	  milliseconds	  (ms).	  	  	  
After	  injury,	  the	  animal	  was	  returned	  to	  the	  surgical	  bench	  and	  placed	  in	  a	  supine	  
position	  with	  gauze	  covering	  the	  wound.	  	  Time	  to	  regain	  paw	  reflexes	  and	  righting	  time	  
were	  recorded	  to	  ensure	  that	  injury	  levels	  remained	  consistent.	  	  The	  animal	  was	  then	  
returned	  to	  anesthesia	  (2.5%	  isoflurane/gas	  mixture)	  via	  nose	  cone	  ventilation,	  and	  the	  
wound	  was	  then	  cleaned	  and	  the	  incision	  sutured.	  	  The	  animal	  was	  removed	  from	  
ventilation	  and,	  after	  normal	  breathing	  returned,	  it	  was	  placed	  in	  its	  cage.	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FIGURE	  2-­‐1:	  	  A	  PHOTOGRAPH	  OF	  THE	  DEVICE	  USED	  TO	  DELIVER	  A	  CONTROLLED	  CORTICAL	  
IMPACT	  (CCI)	  INJURY	  TO	  THE	  ANIMALS	  USED	  IN	  THE	  STUDY.	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MINOCYCLINE	  AND	  BRDU	  INJECTIONS	  
In	  this	  study,	  minocycline	  (Sigma)	  was	  administered	  to	  two	  treatment	  groups	  in	  both	  
the	  young	  and	  the	  aged	  rat	  groups.	  	  In	  the	  first	  treatment	  group,	  rats	  were	  given	  
intraperitoneal	  (IP)	  injections	  at	  30	  minutes	  post	  injury,	  and	  again	  at	  8	  hours	  after	  TBI.	  	  In	  
the	  second	  treatment	  group,	  animals	  were	  given	  injections	  first	  at	  4	  hours	  after	  injury	  and	  
again	  at	  8	  hours.	  	  	  All	  doses	  were	  given	  at	  45mg/kg.	  	  Both	  groups	  were	  also	  subsequently	  
given	  twice-­‐daily	  injections	  on	  the	  first	  and	  second	  days	  post	  injury	  in	  every	  12	  hours,	  at	  
doses	  of	  22.5	  mg/kg.	  	  Animals	  in	  the	  vehicle	  group	  received	  sterile	  saline	  injections	  at	  the	  
same	  time	  points.	  	  Minocycline	  solutions	  for	  injection	  were	  prepared	  by	  dissolving	  15	  mg/ml	  
minocycline	  in	  sterile	  saline.	  
In	  rodents,	  minocycline	  reaches	  peak	  serum	  levels	  about	  2.5	  hours	  after	  injection	  
(IP),	  and	  has	  an	  average	  half-­‐life	  of	  3	  hours	  (Elewa	  et	  al.	  2006).	  	  Several	  studies	  have	  
demonstrated	  improved	  cognitive	  and	  functional	  recovery	  in	  animals	  given	  acute	  
minocycline	  treatments	  after	  injury	  (Sanchez	  Mejia	  et	  al.	  2001;	  Bye	  et	  al.	  2007).	  	  In	  a	  rodent	  
model	  of	  mild,	  blast-­‐induced	  TBI,	  Kovesdi	  and	  colleagues	  (2012)	  saw	  that	  animals	  treated	  
with	  minocycline	  beginning	  4	  hours	  after	  injury,	  for	  four	  days,	  performed	  comparably	  to	  
shams	  in	  three	  different	  behavioral	  tests.	  	  	  
BrdU	  (Sigma)	  was	  also	  administered	  to	  each	  animal	  used	  in	  the	  study	  in	  order	  to	  
label	  cell	  proliferation	  following	  TBI.	  	  BrdU	  (5-­‐bromo-­‐2’-­‐deoxyuridine)	  is	  a	  thymidine	  analog,	  
and	  is	  incorporated	  into	  newly	  replicating	  cells.	  	  At	  two	  days	  post	  injury,	  each	  animal	  
underwent	  4	  i.p.	  injections	  of	  BrdU	  (at	  50	  mg/kg),	  2	  hours	  apart.	  	  All	  animals	  used	  in	  this	  
study	  were	  sacrificed	  at	  3	  days	  post	  injury,	  corresponding	  to	  24	  hours	  after	  the	  last	  BrdU	  or	  
minocycline	  administration.	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TISSUE	  PROCESSING	  
Under	  deep	  anesthesia	  with	  isoflurane,	  the	  rats	  were	  transcardially	  perfused	  with	  400	  
ml	  of	  phosphate	  buffered	  saline	  (PBS)	  followed	  by	  400	  ml	  of	  4%	  paraformaldehyde	  (PFA)	  in	  
PBS.	  	  The	  brains	  were	  then	  removed	  from	  the	  rats’	  skulls	  and	  post-­‐fixed	  in	  the	  same	  fixative,	  
at	  4°C.	  	  Brains	  were	  then	  transferred	  to	  PBS	  before	  being	  prepared	  for	  slicing.	  	  Coronal	  
sectioning	  was	  carried	  out	  at	  a	  thickness	  of	  60μm,	  by	  Vibratome	  (Leica).	  	  The	  slices	  were	  gathered	  into	  four	  serial	  groups	  of	  30	  slices	  each,	  arranged	  in	  five	  24-­‐well	  plates.	  	  Sections	  were	  stored	  in	  PBS	  +	  0.01%	  sodium	  azide,	  at	  4°C.	  
IMMUNOHISTOCHEMISTRY	  	  
Sections	  from	  each	  brain	  were	  selected	  to	  stain	  for	  one	  of	  following	  microglia	  cell	  type	  
markers	  used	  in	  the	  study:	  Iba1,	  ED1,	  Ox6,	  Arg1,	  iNOS,	  CD206,	  CD86.	  	  For	  each	  marker,	  we	  
used	  two	  or	  three	  sections,	  spaced	  720	  μm	  apart,	  from	  each	  brain	  for	  staining.	  
Iba1	  is	  the	  ionized	  calcium-­‐binding	  adaptor	  molecule	  1,	  an	  intracellular	  signaling	  protein	  
expressed	  by	  myeloid	  cells.	  	  It	  is	  constitutively	  expressed,	  but	  up-­‐regulated	  on	  activated	  
cells	  (Donelly	  et	  al.	  2009).	  	  ED1	  is	  a	  marker	  for	  activated	  microglia/macrophages.	  	  It	  stains	  
specifically	  for	  CD68,	  a	  lysosomal	  membrane	  protein	  that	  is	  predominantly	  found	  in	  
phagocytizing	  macrophages	  and	  reactive	  microglia	  (Zhang	  et	  al.	  2012).	  	  Ox6	  is	  an	  MHC	  Class	  
II	  protein,	  and	  also	  a	  marker	  for	  activated	  microglia.	  	  Arginase	  is	  an	  enzyme	  involved	  in	  the	  
metabolism	  of	  arginine,	  and	  a	  marker	  for	  M2	  cells.	  	  BrdU,	  a	  thymidine	  analog,	  is	  a	  marker	  
for	  newly	  proliferating	  cells.	  
We	  originally	  selected	  two	  markers	  for	  each	  microglia	  subtype,	  but	  a	  serial	  dilution	  
performed	  for	  optimization	  revealed	  no	  staining	  for	  three	  of	  the	  four	  markers.	  	  Therefore,	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the	  two	  M1	  markers,	  CD86	  and	  iNOS,	  were	  not	  used	  for	  this	  study	  (Table	  2-­‐2).	  	  CD86	  is	  a	  
cell-­‐surface	  protein	  expressed	  on	  antigen-­‐presenting	  cells	  and	  iNOS	  is	  the	  inducible	  nitric	  
oxide	  synthase,	  an	  enzyme	  that	  also	  uses	  arginine	  as	  a	  substrate,	  driving	  the	  production	  of	  
NO.	  	  Another	  M2	  marker,	  for	  CD206	  –	  the	  mannose	  receptor,	  was	  also	  excluded	  due	  to	  poor	  
staining	  (Table	  2-­‐2).	  	  	  
TABLE	  2-­‐2.	  	  PRIMARY	  ANTIBODIES	  USED	  IN	  IMMUNOSTAINING	  AND	  




Antibody	   Manufacturer	   Dilution	   	  
Iba1	   Wako	  (anti-­‐rabbit)	   1:1000	   General	  microglia/macrophage	  marker	  
ED1	   Millipore	  (anti-­‐mouse)	   1:1000	   General	  microglia/macrophage	  marker	  
Ox6	   Serotec	  (anti-­‐mouse)	   1:1000	   General	  microglia/macrophage	  marker	  
iNOS	   abcam	  (anti-­‐rabbit)	   	   M1	  cell	  type	  marker	  
CD86	   Abnova	  (anti-­‐rabbit	   	   M1	  cell	  type	  marker	  
Arg1	   Santa	  Cruz	  (anti-­‐rabbit)	   1:500	   M2	  cell	  type	  marker	  
CD206	   abcam	  (anti-­‐rabbit	   	   M2	  cell	  type	  marker	  
BrdU	   Dako	  (anti-­‐mouse)	   1:200	   Newly	  proliferating	  cell	  marker	  
BrdU	   Serotec	  (anti-­‐rat)	   1:200	   Newly	  proliferating	  cell	  marker	  
	   26	  
IMMUNOSTAINING	  PROCEDURE	  
Free-­‐floating	  sections	  were	  washed	  with	  phosphate	  buffered	  saline	  (PBS)	  for	  5	  
minutes,	  twice,	  and	  then	  placed	  in	  3%	  hydrogen	  peroxide	  for	  1	  hour	  on	  a	  shaker	  at	  room	  
temperature.	  	  The	  sections	  were	  then	  washed	  with	  PBS	  +	  0.3%	  Triton	  100	  for	  5	  minutes,	  
three	  times.	  	  The	  sections	  were	  then	  blocked	  overnight	  at	  4°C	  on	  a	  shaker	  in	  a	  blocking	  
buffer	  of	  PBS	  +	  0.3%	  Triton	  100	  and	  5%	  normal	  horse	  serum	  or	  fetal	  bovine	  serum.	  	  	  
	   The	  next	  day,	  sections	  were	  brought	  to	  room	  temperature	  and	  another	  wash	  with	  
PBS	  +	  0.3%	  Triton	  100	  was	  performed	  for	  10	  minutes,	  3	  times.	  	  After	  the	  wash,	  the	  primary	  
antibody	  was	  added	  (Figure	  2).	  	  Arg1	  (Santa	  Cruz;	  anti-­‐rabbit)	  was	  added	  at	  a	  1:500	  dilution	  
in	  blocking	  solution,	  and	  Iba1	  (Wako;	  anti-­‐rabbit),	  ED1	  (Millipore;	  anti-­‐mouse),	  and	  Ox6	  
(Serotec;	  anti-­‐mouse)	  were	  added	  at	  a	  1:1000	  dilution.	  	  The	  sections	  were	  allowed	  to	  
incubate	  at	  4°C	  on	  a	  shaker	  for	  at	  least	  48	  hours.	  	  	  
	   Sections	  were	  then	  brought	  back	  to	  room	  temperature	  and	  rinsed	  in	  PBS	  +	  0.3%	  
Triton	  100	  for	  10	  minutes,	  three	  times.	  	  Tissue	  was	  blocked	  again	  for	  3	  hours	  at	  room	  
temperature	  on	  a	  shaker,	  in	  the	  same	  blocking	  solution	  as	  previously	  described.	  	  After	  
blocking,	  the	  appropriate	  secondary	  biotinylated	  antibody	  was	  added.	  	  For	  Arg1-­‐	  and	  Iba1-­‐
stained	  sections,	  biotinylated	  anti-­‐rabbit	  IgG	  (Dako)	  was	  added	  at	  a	  1:200	  dilution	  in	  
blocking	  solution.	  	  For	  ED1-­‐	  and	  Ox6-­‐stained	  sections,	  biotinylated	  anti-­‐mouse	  IgG	  (Dako)	  
was	  added	  at	  a	  1:200	  dilution.	  	  Sections	  incubated	  with	  the	  secondary	  antibody	  overnight,	  
at	  4°C,	  on	  a	  shaker.	  	  	  
	   The	  next	  morning,	  the	  sections	  were	  brought	  back	  to	  room	  temperature	  and	  washed	  
with	  PBS	  for	  10	  minutes,	  three	  times.	  	  A	  1:200	  solution	  of	  avidin-­‐biotin	  substrate	  (ABC	  Kit,	  
Vector	  Laboratories;	  made	  30	  minutes	  before	  use)	  in	  PBS	  was	  then	  added,	  and	  sections	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were	  allowed	  to	  incubate	  at	  room	  temperature	  for	  2	  hours,	  on	  a	  shaker.	  	  After	  incubation	  
with	  ABC,	  sections	  were	  washed	  three	  times	  with	  PBS,	  for	  ten	  minutes	  each.	  	  At	  this	  point,	  a	  
DAB	  solution	  was	  added	  to	  the	  sections,	  one	  tray	  at	  a	  time.	  	  The	  liquid	  DAB	  (Vector	  
Laboratories)	  was	  prepared	  by	  adding	  the	  following	  solutions	  to	  5ml	  of	  nanopure	  water:	  	  2	  
drops	  of	  the	  Buffer	  Stock	  Solution,	  4	  drops	  of	  the	  DAB	  Stock	  Solution,	  and	  2	  drops	  of	  the	  
hydrogen	  peroxide	  solution,	  mixing	  well	  after	  each	  addition.	  	  The	  sections	  were	  monitored	  
under	  a	  microscope	  while	  they	  incubated	  with	  the	  liquid	  DAB	  solution,	  and	  were	  quenched	  
with	  PBS	  when	  they	  were	  sufficiently	  stained.	  	  The	  sections	  were	  washed	  with	  PBS	  for	  5	  
minutes,	  three	  times,	  and	  stored	  at	  4°C	  until	  ready	  for	  mounting.	  	  The	  sections	  were	  then	  
were	  rinsed	  in	  distilled	  water	  just	  before	  being	  mounted	  onto	  glass	  microscope	  slides,	  2-­‐3	  
sections	  per	  slide.	  
COUNTERSTAINING	  PROCEDURE	  
Slides	  with	  mounted	  sections	  were	  arranged	  in	  a	  rack	  and	  placed	  in	  distilled	  water	  
for	  2	  minutes.	  	  Slides	  were	  then	  placed	  in	  a	  0.1%	  Cresyl	  Violet	  solution	  for	  one	  minute.	  	  After	  
a	  brief	  rinse	  under	  tap	  water	  (one	  minute)	  and,	  finally,	  distilled	  water	  (30	  seconds),	  the	  
slides	  were	  placed	  in	  two	  75%	  baths	  and	  one	  95%	  EtOH	  bath	  for	  one	  minute	  each.	  	  Sections	  
were	  then	  differentiated	  in	  acid	  alcohol	  (95%	  EtOH	  +	  a	  few	  drops	  of	  HCl)	  to	  remove	  almost	  
all	  of	  the	  background	  stain.	  	  The	  slides	  were	  then	  run	  through	  two	  baths	  of	  100%	  EtOH	  for	  
one	  minute	  each,	  and	  then	  placed	  in	  Citra	  Solv	  for	  2.5	  minutes	  and	  5	  minutes.	  	  Slides	  were	  
then	  coverslipped	  using	  Permount	  (Fisher).	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IMMUNOFLUORESCENT	  DOUBLE	  STAINING	  
Fluorescent	  double	  staining	  was	  carried	  out	  in	  order	  to	  assess	  whether	  the	  cell-­‐type-­‐
specific	  markers	  co-­‐localized	  with	  BrdU,	  a	  marker	  for	  newly	  proliferating	  cells.	  	  The	  sections	  
were	  stained	  for	  BrdU	  and	  one	  other	  cell	  type	  marker	  (Iba1,	  ED1,	  or	  ARG1).	  	  One	  section	  
from	  each	  selected	  brain	  was	  also	  doubled	  labeled	  with	  ARG1	  and	  ED1	  to	  assess	  co-­‐
localization	  of	  the	  M2	  cell-­‐type	  marker	  with	  a	  general	  microglia	  cell	  marker.	  
For	  the	  BrdU	  double	  labeling,	  the	  free	  floating	  sections	  were	  rinsed	  twice	  with	  PBS	  
for	  5	  minutes,	  and	  then	  denatured	  in	  a	  50%	  Formamide	  solution	  (in	  water	  and	  20x	  saline	  
sodium	  citrate	  (SSC))	  for	  one	  hour	  in	  a	  65°C	  oven.	  	  The	  sections	  were	  then	  removed	  from	  
heat	  and	  rinsed	  twice	  with	  2x	  SSC	  for	  5	  minutes	  before	  being	  placed	  in	  2N	  HCl	  for	  30	  
minutes	  in	  an	  oven	  set	  at	  37°C.	  	  	  
The	  sections	  were	  removed	  from	  the	  oven,	  and	  all	  sections	  (including	  those	  not	  
being	  labeled	  with	  BrdU)	  were	  rinsed	  with	  PBS	  for	  5	  minutes,	  twice.	  	  The	  sections	  were	  then	  
quenched	  in	  3%	  hydrogen	  peroxide,	  washed	  with	  PBS	  +	  0.3%	  Triton	  100,	  and	  blocked	  
overnight	  as	  described	  in	  the	  previous	  immunostaining	  procedure.	  	  	  
The	  next	  day,	  the	  primary	  antibody	  solution	  was	  added,	  made	  in	  the	  same	  blocking	  
buffer	  as	  described	  earlier.	  	  For	  BrdU	  double	  labeling	  with	  Arginase	  or	  Iba1,	  anti-­‐mouse	  
BrdU	  (Dako;	  1:200)	  was	  used,	  and	  for	  double	  labeling	  with	  ED1,	  anti-­‐rat	  BrdU	  (Serotec;	  
1:200)	  was	  used.	  	  All	  other	  cell	  type	  markers	  were	  used	  at	  the	  same	  dilutions	  as	  normal	  
immunostaining.	  	  Sections	  were	  allowed	  to	  incubate	  with	  the	  primary	  antibody	  solutions	  for	  
at	  least	  48	  hours,	  at	  4°C	  on	  a	  shaker.	  	  After	  incubation,	  sections	  were	  rinsed	  with	  PBS	  +	  0.3%	  
Triton	  100	  for	  10	  minutes,	  three	  times.	  	  The	  sections	  were	  then	  allowed	  to	  block	  at	  room	  
temperature	  on	  a	  shaker	  for	  3	  hours	  before	  adding	  the	  secondary	  antibody	  solutions.	  	  For	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BrdU/Arginase,	  BrdU/Iba1,	  and	  Arginase/ED1	  labeling,	  two	  Alexa	  fluorophore-­‐conjugated	  
secondary	  antibodies	  were	  used	  (anti-­‐mouse	  IgG	  488	  and	  anti-­‐rabbit	  IgG	  568;	  1:200;	  
Molecular	  Probes)	  were	  used.	  	  For	  BrdU/ED1	  double	  labeling,	  the	  Alexa	  fluorophore-­‐
conjugated	  anti-­‐rat	  IgG	  488	  and	  anti-­‐mouse	  IgG	  568	  (1:200;	  Molecular	  Probes)	  were	  used.	  	  	  
Sections	  were	  then	  washed	  with	  PBS	  for	  10	  minutes,	  three	  times,	  rinsed	  with	  
distilled	  water	  twice,	  and	  then	  mounted	  on	  a	  glass	  microscope	  slide.	  	  Mounted	  sections	  
were	  coverslipped	  using	  Vectashield	  mounting	  medium	  (Vector	  Laboratories)	  and	  sealed	  
with	  clear	  nail	  polish,	  before	  being	  stored	  in	  a	  -­‐20°C	  freezer.	  
Sections	  were	  examined	  by	  confocal	  microscopy	  in	  order	  to	  quantify	  the	  percentage	  
of	  new,	  BrdU-­‐labeled	  cells	  that	  had	  differentiated	  into	  a	  specific	  subtype.	  In	  the	  cortex,	  the	  
peri-­‐contusional	  area	  was	  assessed	  for	  BrdU+	  cells	  and	  each	  cell	  was	  manually	  examined	  for	  
co-­‐labeling	  with	  another	  cell-­‐type-­‐specific	  marker.	  	  The	  percentage	  of	  double-­‐labeled	  cells	  
was	  calculated	  as	  the	  number	  of	  BrdU+	  cells	  that	  also	  co-­‐labeled	  with	  a	  cell-­‐type-­‐specific	  
marker	  against	  the	  total	  number	  of	  BrdU+	  cells	  in	  the	  same	  section.	  	  The	  percentages	  of	  
double-­‐labeled	  cells	  in	  vehicle	  cortical	  tissue	  were	  compared	  to	  double-­‐labeled	  cells	  in	  
minocycline-­‐treated	  animals.	  
A	  section	  fluorescently	  labeled	  for	  both	  ARG1	  and	  ED1	  was	  also	  examined	  for	  co-­‐
labeling.	  	  The	  peri-­‐contusional	  cortex	  was	  examined	  for	  co-­‐localization	  of	  the	  two	  markers	  
and	  only	  those	  cells	  with	  explicit	  staining	  for	  both	  markers	  were	  counted	  as	  double-­‐labeled.	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DENSITOMETRY	  ANALYSIS	  
For	  analysis	  of	  IHC,	  we	  used	  Digital	  Image	  Analysis	  (DIA),	  as	  described	  by	  Donelly	  et	  al.	  
(2009).	  	  In	  this	  comparative	  study,	  DIA	  was	  found	  to	  be	  consistently	  the	  most	  sensitive	  and	  
least	  variable,	  as	  well	  as	  most	  time-­‐efficient,	  when	  compared	  to	  standard	  profile	  counting	  
(PC)	  and	  the	  unbiased	  sampling	  technique	  (UST).	  
Images	  were	  taken	  with	  the	  Olympus	  DP	  Controller	  program,	  employing	  an	  Olympus	  
IX71	  microscope	  using	  a	  4x	  objective.	  	  Two	  cortical	  tissue	  images	  were	  taken	  when	  there	  
was	  an	  injury	  that	  caused	  a	  concavity	  to	  form.	  	  One	  image	  was	  taken	  on	  either	  side	  of	  the	  
concavity.	  	  For	  shams	  and	  those	  injured	  animals	  that	  suffered	  a	  mild	  injury	  and	  lacked	  an	  
injury	  concavity,	  only	  one	  cortical	  tissue	  image	  was	  taken.	  	  For	  all	  sections,	  one	  image	  of	  the	  
dentate	  gyrus	  of	  the	  hippocampus	  was	  taken.	  	  For	  each	  staining	  group,	  images	  were	  kept	  at	  
a	  consistent	  exposure,	  and	  optimized	  for	  white	  balance	  and	  high	  contrast.	  	  	  
DIA	  was	  completed	  using	  the	  IP	  Lab	  program	  (Scanalytics).	  	  	  Images	  were	  converted	  to	  
gray	  scale	  and	  the	  XY	  units	  were	  defined,	  using	  a	  predetermined	  pixel:μm	  ratio	  (1	  pixel	  =	  
1.61	  μm).	  	  A	  line	  was	  then	  drawn	  around	  the	  region	  of	  interest	  (ROI),	  which	  in	  cortical	  
images	  included	  the	  visible	  ipsilateral	  cortical	  tissue,	  and	  in	  hippocampal	  images	  included	  
the	  entire	  dentate	  gyrus.	  	  	  
The	  program	  was	  then	  used	  to	  determine	  a	  threshold	  value	  that	  included	  all	  positively	  
stained	  cells	  in	  the	  densitometry	  measurements,	  with	  as	  little	  background	  as	  possible.	  	  For	  
Iba1	  staining,	  the	  “max”	  for	  this	  segmentation	  step	  was	  held	  constant	  at	  190,	  and	  for	  all	  
other	  staining	  the	  “max”	  was	  held	  constant	  at	  155.	  	  After	  segmentation,	  the	  IP	  Lab	  program	  
was	  used	  to	  analyze	  the	  ROI	  for	  the	  percent	  area	  occupied	  by	  the	  positively	  labeled	  cells.	  	  
This	  data	  was	  then	  used	  for	  the	  statistical	  analyses.	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STATISTICAL	  ANALYSIS	  
Data	  was	  preliminarily	  analyzed	  using	  post-­‐hoc	  student	  two-­‐tailed	  t-­‐tests,	  assuming	  
equal	  variances.	  	  T-­‐test	  data	  was	  used	  to	  compare	  differences	  between	  the	  two	  age	  groups,	  
within	  each	  injury	  group.	  	  Two-­‐way	  ANOVA	  (analysis	  of	  variance)	  with	  LSD	  post-­‐hoc	  tests	  
were	  also	  performed,	  to	  analyze	  the	  differences	  in	  staining	  densities	  among	  the	  treatment	  
groups,	  within	  an	  age	  group,	  for	  each	  marker.	  	  P-­‐values	  less	  than	  0.05	  were	  considered	  
statistically	  significant.	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RESULTS	  
The	  inflammatory	  response	  is	  known	  to	  be	  involved	  in	  secondary	  damage	  following	  
traumatic	  brain	  injury,	  contributing	  to	  reduced	  or	  prolonged	  regeneration	  and	  recovery.	  	  
Studies	  have	  also	  shown	  that	  the	  aged	  brain	  has	  higher	  levels	  of	  systemic	  inflammation,	  
which	  may	  make	  it	  poised	  to	  exhibit	  a	  robust	  and	  exaggerated	  inflammatory	  response	  after	  
injury.	  	  In	  the	  current	  study,	  we	  sought	  to	  determine	  the	  effects	  of	  an	  anti-­‐inflammatory	  
drug,	  minocycline,	  on	  the	  inflammatory	  response	  in	  both	  young	  and	  aged	  rats	  in	  the	  acute	  
stage	  following	  a	  controlled	  cortical	  impact	  (CCI)	  injury.	  	  We	  used	  two	  treatment	  groups,	  the	  
first	  receiving	  the	  initial	  dose	  of	  minocycline	  at	  30	  minutes	  post	  injury,	  and	  the	  second	  
receiving	  the	  initial	  dose	  at	  4	  hours	  post	  injury.	  	  The	  animals	  used	  were	  Fisher	  344	  rats,	  aged	  
3	  months	  (corresponding	  to	  a	  young	  adult	  human)	  and	  20	  months	  (corresponding	  to	  a	  
middle-­‐aged	  human)	  (Hamm	  et	  al.	  1991).	  	  	  
We	  examined	  the	  inflammatory	  cell	  response	  using	  the	  general	  inflammatory	  cell	  
markers	  including	  Iba1,	  ED1,	  OX6.	  	  We	  also	  used	  M1	  subtype	  markers	  iNOS	  and	  CD86,	  M2	  
subtype	  markers	  Arg1	  and	  CD206.	  	  However,	  the	  antibodies	  we	  used	  for	  iNOS,	  CD86	  and	  
CD206	  did	  not	  work	  immunohistochemically	  on	  rat	  brain	  sections.	  	  	  To	  determine	  whether	  
minocycline	  treatment	  affects	  generation	  of	  the	  subtypes	  of	  microglial	  cells,	  double	  labeling	  
of	  ED1,	  Iba1	  with	  BrdU,	  as	  well	  as	  ED1	  with	  Arg1	  were	  performed.	  	  	  
	   In	  our	  assessment,	  we	  examined	  two	  regions	  of	  each	  brain	  sections:	  the	  peri-­‐
contusional	  cortical	  tissue	  and	  the	  ipsilateral	  dentate	  gyrus	  of	  the	  hippocampus.	  	  These	  
areas	  were	  the	  focus	  because	  high	  level	  of	  inflammatory	  cell	  reaction	  around	  the	  lesion	  area	  
after	  injury,	  and	  the	  hippocampus	  has	  a	  high	  number	  of	  resident	  microglia.	  	  The	  
hippocampus	  is	  also	  particularly	  vulnerable	  to	  injury	  because	  it	  is	  a	  site	  of	  continuous	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neuronal	  proliferation	  throughout	  the	  lifespan.	  	  Digital	  image	  analysis	  (DIA)	  was	  used	  to	  
determine	  the	  proportional	  area	  of	  positive	  staining	  in	  each	  region,	  and	  the	  
intensity/expression	  level	  of	  each	  marker	  was	  expressed	  as	  percentages.	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   Peri-­‐Injury	  Cortex	   Ipsilateral	  Dentate	  Gyrus	  




















	   	   	   	   	   	   	   	  
Iba1	   −	   −	   −	   ê	   −	   −	   −	   ê	  




	   	   	   	   	   	   	   	  
ED1	   −	   −	   −	   ê	   −	   −	   −	   −	  
OX6	   ê	   ê	   ê	   ê	   −	   −	   −	   −	  
	   	   	   	   	   	   	   	   	  
M2	  
Marker	  
	   	   	   	   	   	   	   	  
ARG1	   −	   −	   −	   −	   −	   −	   −	   −	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TABLE	  3-­‐1:	  Table	  shows	  the	  observed	  effect	  of	  minocycline	  treatments	  (30-­‐minute	  and	  4-­‐
hour)	  on	  cell-­‐type-­‐specific	  marker	  staining,	  compared	  to	  vehicle-­‐treated	  animals.	  	  Arrows	  
indicate	  either	  statistically	  significant	  increases	  (é)	  or	  decreases	  (ê)	  in	  staining,	  and	  lines	  
(−)	  indicate	  no	  significant	  changes.	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EFFECT	  OF	  MINOCYCLINE	  ON	  MICROGLIA	  STAINING	  IN	  YOUNG	  AND	  
AGED	  RATS	  FOLLOWING	  CCI	  –	  IBA1	  
	   Iba1	  recognizes	  the	  ionized	  calcium-­‐binding	  adaptor	  molecule	  1,	  and	  detects	  both	  
resting	  and	  activated	  microglia	  as	  well	  as	  different	  subpopulations	  of	  microglia	  (Ito	  et	  al.	  
1998).	  	  In	  previous	  studies,	  Iba1+	  cells	  with	  a	  ramified	  morphology	  are	  normally	  observed	  
throughout	  the	  parenchyma	  of	  the	  cerebrum	  and	  hippocampus	  of	  healthy	  brains	  (Ito	  et	  al.	  
1998).	  	  After	  injury,	  Iba1+	  staining	  intensifies	  around	  the	  lesion	  site	  and	  the	  microglia	  take	  
on	  a	  more	  amoeboid	  morphology	  on	  the	  ipsilateral	  side	  (Ito	  et	  al.	  1998).	  	  	  
In	  this	  study,	  Iba1	  staining	  was	  seen	  throughout	  the	  cortical	  tissue	  and	  hippocampus	  
of	  all	  animals	  (Figure	  3-­‐1).	  	  In	  the	  cortex,	  staining	  was	  lightest	  in	  the	  sham	  and	  heavier	  in	  the	  
three	  injury	  groups.	  	  The	  staining	  in	  the	  ipsilateral	  dentate	  gyrus	  was	  similarly	  heaviest	  in	  
the	  injury	  groups	  and	  lightest	  in	  sham.	  	  Also	  in	  the	  dentate	  gyrus,	  we	  observed	  a	  change	  in	  
staining	  pattern	  in	  the	  injured	  animals	  that	  was	  not	  seen	  in	  shams.	  	  Specifically,	  staining	  
became	  denser	  in	  a	  band	  surrounding	  the	  Granular	  Cell	  Layer.	  	  	  
In	  the	  peri-­‐lesion	  cortical	  tissue	  of	  young	  rats	  (3M),	  all	  three	  injury	  groups	  showed	  
intense	  Ib1a	  staining	  in	  this	  region	  compared	  to	  sham	  (Figure	  3-­‐1).	  	  Densitometry	  analysis	  
revealed	  that	  a	  significantly	  higher	  densities	  of	  Iba1+	  staining	  in	  the	  vehicle-­‐treated	  animals	  
(p=0.049),	  animals	  treated	  with	  minocycline	  beginning	  at	  30	  minutes	  post-­‐injury	  (p=0.032),	  
and	  animals	  treated	  with	  minocycline	  beginning	  at	  4	  hours	  post-­‐injury	  (p=0.0009),	  
compared	  to	  sham	  (Figure	  3-­‐2).	  	  Similarly,	  in	  the	  ipsilateral	  dentate	  gyrus	  of	  young	  rats,	  all	  
three	  injury	  groups	  had	  higher	  staining	  densities	  of	  Iba1+	  cells,	  compared	  to	  shams	  (Figures	  
3-­‐2	  and	  3-­‐3).	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   In	  the	  aged	  group,	  in	  the	  cortical	  tissue,	  similar	  to	  young	  animals,	  all	  injured	  groups	  
had	  increased	  Iba1	  staining	  compared	  to	  sham	  (Figure	  3-­‐3).	  	  Densitometry	  analysis	  showed	  
that	  compared	  to	  sham,	  the	  vehicle	  (p=0.016)	  and	  minocycline	  30	  minute	  (p=0.031)	  groups	  
had	  statistically	  higher	  Iba1+	  staining	  densities	  (Figure	  3-­‐4).	  	  The	  average	  staining	  density	  for	  
the	  minocycline	  4-­‐hour	  group	  was	  higher	  than	  sham,	  but	  was	  not	  significant.	  	  Among	  injured	  
groups,	  animals	  received	  minocycline	  treatment	  at	  4	  hours	  post-­‐injury	  had	  significantly	  
reduced	  Iba1+	  staining	  density	  compared	  to	  the	  vehicle	  group	  (p=0.002)	  and	  the	  30-­‐min	  
treatment	  group	  (p=0.001).	  	  In	  the	  ipsilateral	  hippocampal	  dentate	  gyrus,	  aged	  animals	  in	  
injured	  groups	  had	  more	  intense	  Iba1	  staining	  compared	  to	  sham	  (Figure	  3-­‐4).	  	  	  Statistically	  
significant	  higher	  Iba1+	  staining	  densities	  were	  only	  found	  in	  the	  vehicle	  group	  compared	  to	  
shams	  (p=0.017)	  (Figure	  3-­‐4).	  	  Again,	  the	  4-­‐hour	  minocycline	  treatment	  group	  had	  
significantly	  lower	  staining	  density	  compared	  to	  both	  the	  vehicle	  group	  (p=0.003)	  and	  the	  
30-­‐minute	  minocycline	  treatment	  group	  (p=0.005).	  	  
	   We	  also	  examined	  differences	  in	  the	  proportional	  Iba1+	  area,	  in	  the	  two	  regions	  of	  
interest,	  between	  the	  young	  and	  aged	  animals	  in	  each	  treatment	  group.	  	  The	  aged	  animals	  
generally	  had	  higher	  Iba1+	  staining	  densities	  in	  shams,	  vehicles,	  and	  the	  30-­‐minute	  
minocycline	  treatment	  group.	  	  Following	  minocycline	  treatment,	  the	  aged	  animals	  had	  
reduced	  Iba1+	  staining	  density	  in	  the	  4-­‐hour	  minocycline	  treatment	  group,	  compared	  to	  the	  
same	  treatment	  regime	  in	  young	  animals,	  and	  was	  significant	  in	  the	  peri-­‐lesion	  cortex	  
(p=0.0013).	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FIGURE	  3-­‐1:	  PATTERN	  OF	  IBA1+	  STAINING	  IN	  THE	  PERI-­‐LESION	  CORTEX	  AND	  IPSILATERAL	  
DENTATE	  GYRUS	  (DG)	  IN	  YOUNG	  (3M)	  ANIMALS	  AT	  3	  DAYS	  POST-­‐INJURY.	  	  	  
Representative	  micrograph	  images	  of	  Iba1	  staining	  in	  the	  peri-­‐lesion	  cortical	  region	  (upper	  
panels)	  and	  the	  ipsilateral	  DG	  (lower	  panels)	  from	  shams	  (N=3),	  and	  injured	  animals	  treated	  
with	  vehicle	  (N=5),	  minocycline	  beginning	  at	  30	  minutes	  after	  injury	  (N=5),	  and	  minocycline	  
beginning	  at	  4	  hours	  after	  injury	  (N=4).	  	  For	  the	  sham	  animal,	  a	  representative	  cortical	  tissue	  
area	  directly	  above	  the	  hippocampus	  was	  selected	  for	  comparison	  with	  injured	  animals.	  	  
Strong	  Iba1+	  staining	  was	  seen	  in	  all	  injured	  groups,	  compared	  to	  shams.	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FIGURE	  3-­‐2:	  DENSITOMETRY	  ANALYSIS	  OF	  IBA1	  STAINING	  INTENSITY	  IN	  THE	  IPSILATERAL	  
PERI-­‐LESION	  CORTEX	  AND	  IPSILATERAL	  DENTATE	  GYRUS	  (DG)	  OF	  YOUNG	  RATS	  (3	  M).	  	  
Values	  are	  given	  as	  percent	  of	  region	  of	  interest	  (ROI)	  occupied	  by	  the	  positively	  labeled	  
cells.	  	  (A)	  In	  the	  peri-­‐lesion	  cortex	  region	  of	  young	  animals,	  the	  vehicle-­‐treated	  animals	  and	  
animals	  in	  both	  minocycline	  treatment	  groups	  had	  significantly	  higher	  intensity	  of	  Iba+	  cells	  
staining	  compared	  to	  shams	  (*p<0.05,	  **p<0.01).	  	  (B)	  In	  the	  hippocampus	  of	  young	  animals,	  
the	  percentages	  of	  Iba	  staining	  intensity	  were	  higher	  in	  all	  injury	  groups	  compared	  to	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FIGURE	  3-­‐3:	  PATTERN	  OF	  IBA1+	  STAINING	  IN	  THE	  PERI-­‐LESION	  CORTEX	  AND	  IPSILATERAL	  
DENTATE	  GYRUS	  (DG)	  IN	  AGED	  (20)	  ANIMALS	  AT	  3	  DAYS	  POST-­‐INJURY.	  	  	  
Representative	  micrograph	  images	  of	  Iba1	  staining	  in	  the	  peri-­‐lesion	  cortical	  region	  (upper	  
panels)	  and	  the	  ipsilateral	  DG	  (lower	  panels)	  from	  sham	  (N=2),	  injured	  animals	  treated	  with	  
vehicle	  (N=4),	  minocycline	  beginning	  at	  30	  minutes	  after	  injury	  (N=4),	  and	  minocycline	  
beginning	  at	  4	  hours	  after	  injury	  (N=4).	  	  For	  the	  sham	  animal,	  a	  representative	  cortical	  tissue	  
area	  directly	  above	  the	  hippocampus	  was	  selected	  for	  comparison	  with	  injured	  animals.	  	  
Strong	  Iba1+	  staining	  was	  seen	  in	  all	  injured	  groups,	  compared	  to	  shams.	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FIGURE	  3-­‐4:	  DENSITOMETRY	  ANALYSIS	  OF	  IBA1	  LABELING	  INTENSITY	  IN	  THE	  IPSILATERAL	  
CORTICAL	  TISSUE	  AND	  IPSILATERAL	  DENTATE	  GYRUS	  OF	  AGED	  RATS	  (20	  MONTHS).	  	  	  
Values	  are	  given	  as	  percent	  of	  ROI	  area	  occupied	  by	  the	  positively	  labeled	  cells.	  	  (A)	  In	  the	  
cortical	  tissue	  of	  aged	  animals,	  the	  vehicle-­‐treated	  animals	  and	  TBI+Mino-­‐30min	  groups	  had	  
significantly	  higher	  densities	  of	  Iba1+	  cells	  compared	  to	  shams	  (*p<0.05).	  	  The	  density	  of	  
Iba1	  staining	  in	  the	  TBI+Mino-­‐4hr	  group	  was	  also	  higher	  compared	  to	  shams,	  but	  it	  was	  not	  
significant.	  	  	  Among	  three	  injury	  groups,	  the	  TBI+Mino-­‐4hr	  group	  had	  a	  significantly	  lower	  
density	  of	  Iba1+	  cells	  compared	  to	  vehicles	  and	  TBI+Mino-­‐30min	  group	  (**p<0.01).	  	  (B)	  In	  
the	  hippocampus	  of	  aged	  rats,	  in	  three	  injure	  groups,	  only	  the	  TBI-­‐Vehicle	  group	  had	  a	  
significantly	  higher	  intensity	  of	  Iba1+	  staining	  compared	  to	  sham	  (*p<0.05).	  	  In	  this	  region,	  
among	  injured	  groups,	  the	  TBI+Mino-­‐4hr	  group	  had	  a	  significantly	  lower	  density	  of	  Iba1+	  
cells	  compared	  to	  both	  vehicles	  and	  TBI+Mino-­‐30min	  animals	  (**p<0.01).	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EFFECT	  OF	  MINOCYCLINE	  ON	  MICROGLIA	  STAINING	  IN	  YOUNG	  AND	  
AGED	  RATS	  FOLLOWING	  CCI	  –	  ED1	  
	   ED1	  is	  a	  general	  macrophage	  marker	  that	  labels	  infiltrating	  macrophages	  and	  
activated	  microglia	  (Urrea	  et	  al.	  2007).	  	  It	  recognizes	  CD68,	  a	  lysosomal	  membrane	  protein	  
in	  macrophages.	  	  	  In	  previous	  studies,	  ED1+	  staining	  has	  been	  restricted	  to	  the	  area	  just	  
surrounding	  the	  contusion	  (Urrea	  et	  al.	  2007).	  	  ED1+	  microglia	  near	  the	  lesion	  have	  been	  
observed	  to	  have	  an	  amoeboid	  morphology,	  whereas	  cells	  further	  away	  are	  smaller	  and	  are	  
characterized	  by	  thick,	  elongated	  processes	  (Zhang	  et	  al.	  2012).	  	  	  
In	  sections	  examined	  in	  sham	  animals,	  ED1+	  staining	  was	  very	  low	  in	  both	  cortical	  
and	  hippocampal	  regions	  (Figures	  3-­‐5	  and	  3-­‐7).	  	  In	  the	  cortex,	  the	  positively	  labeled	  cells	  
were	  concentrated	  at	  the	  injury	  site	  edge,	  with	  sparser	  staining	  moving	  away	  from	  the	  
cavity	  (Figures	  3-­‐5	  and	  3-­‐7).	  	  In	  both	  age	  groups,	  we	  see	  the	  heaviest	  staining	  seen	  in	  vehicle	  
groups	  and	  lighter	  staining	  in	  the	  minocycline	  treatment	  groups.	  	  A	  similar	  pattern	  was	  seen	  
among	  the	  groups	  when	  examining	  the	  dentate	  gyrus	  (Figures	  3-­‐5	  and	  3-­‐7),	  although	  
staining	  was	  not	  concentrated	  in	  any	  particular	  spot	  in	  the	  hippocampus.	  	  We	  therefore	  only	  
compared	  the	  two	  minocycline	  treatment	  groups	  to	  the	  vehicle-­‐treated	  group.	  	  
In	  three-­‐month-­‐old	  rats,	  in	  the	  injured	  cortical	  regions,	  there	  were	  no	  statistically	  
significant	  differences	  among	  the	  three	  injury	  groups,	  due	  to	  high	  standard	  errors.	  	  
Examining	  the	  young	  animal	  dentate	  gyri,	  we	  also	  found	  no	  significant	  differences	  among	  
the	  vehicle-­‐and	  minocycline-­‐treated	  groups.	  	  For	  the	  20-­‐month-­‐old	  animals	  in	  the	  two	  
regions,	  a	  similar	  comparison	  was	  made	  only	  among	  the	  injured	  groups	  examined.	  	  	  In	  the	  
cortex,	  among	  three	  injured	  groups,	  both	  minocycline	  treatment	  groups	  had	  lower	  level	  of	  
ED1	  staining	  compared	  to	  vehicle	  group,	  and	  the	  difference	  was	  statistically	  significant	  in	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the	  4-­‐hour	  minocycline	  treatment	  group	  (p=0.047,	  Fig3-­‐8A).	  	  There	  were	  no	  statistically	  
significant	  differences	  between	  two	  minocycline	  treatment	  groups.	  	  In	  the	  DG,	  no	  significant	  
differences	  were	  found	  among	  any	  of	  the	  injury	  groups	  (Fig.3-­‐8B).	  	  Also,	  a	  comparison	  for	  
each	  treatment	  group,	  between	  aged	  and	  young	  rats,	  revealed	  no	  significant	  differences	  in	  
staining	  ED1+	  staining	  density.	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FIGURE	  3-­‐5:	  PATTERN	  OF	  ED1+	  STAINING	  IN	  THE	  PERI-­‐LESION	  CORTEX	  AND	  IPSILATERAL	  
DENTATE	  GYRUS	  (DG)	  IN	  YOUNG	  (3M)	  ANIMALS	  AT	  3	  DAYS	  POST-­‐INJURY.	  	  	  
Representative	  micrograph	  images	  of	  ED1	  staining	  in	  the	  peri-­‐lesion	  cortical	  region	  (upper	  
panels)	  and	  the	  ipsilateral	  DG	  (lower	  panels)	  from	  shams	  (N=2),	  and	  injured	  animals	  treated	  
with	  vehicle	  (N=4),	  minocycline	  beginning	  at	  30	  minutes	  after	  injury	  (N=5),	  and	  minocycline	  
beginning	  at	  4	  hours	  after	  injury	  (N=3).	  	  For	  the	  sham	  animal,	  a	  representative	  cortical	  tissue	  
area	  directly	  above	  the	  hippocampus	  was	  selected	  for	  comparison	  with	  injured	  animals.	  	  In	  
both	  regions,	  strong	  ED1	  staining	  was	  seen	  in	  all	  injured	  groups.	  ED1	  staining	  was	  negligible	  
in	  the	  shams.	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FIGURE	  3-­‐6:	  DENSITOMETRY	  ANALYSIS	  OF	  ED1	  STAINING	  INTENSITY	  IN	  THE	  IPSILATERAL	  
CORTICAL	  TISSUE	  AND	  IPSILATERAL	  DENTATE	  GYRUS	  OF	  YOUNG	  RATS	  (3	  MONTHS).	  	  	  
Values	  are	  given	  as	  percent	  of	  ROI	  area	  occupied	  by	  the	  positively	  labeled	  cells.	  	  (A)	  In	  the	  
cortical	  tissue	  of	  young	  rats,	  proportional	  areas	  of	  ED1+	  cells	  were	  lower	  in	  both	  
minocycline	  treatment	  groups,	  compared	  to	  vehicle,	  but	  did	  not	  reach	  significance.	  	  (B)	  In	  
the	  dentate	  gyrus	  of	  young	  animals,	  all	  injury	  groups	  again	  had	  higher	  densities	  of	  ED1+	  
staining.	  Minocycline	  groups	  had	  slightly	  lower	  staining	  intensity	  than	  vehicle	  group	  but	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FIGURE	  3-­‐7:	  PATTERN	  OF	  ED1+	  STAINING	  IN	  THE	  PERI-­‐LESION	  CORTEX	  AND	  IPSILATERAL	  
DENTATE	  GYRUS	  (DG)	  IN	  AGED	  (20M)	  ANIMALS	  AT	  3	  DAYS	  POST-­‐INJURY.	  	  	  
Representative	  micrograph	  images	  of	  ED1	  staining	  in	  the	  peri-­‐lesion	  cortical	  region	  (upper	  
panels)	  and	  the	  ipsilateral	  DG	  (lower	  panels)	  from	  shams	  (N=1),	  and	  injured	  animals	  treated	  
with	  vehicle	  (N=4),	  minocycline	  beginning	  at	  30	  minutes	  after	  injury	  (N=4),	  and	  minocycline	  
beginning	  at	  4	  hours	  after	  injury	  (N=4).	  	  For	  the	  sham	  animal,	  a	  representative	  cortical	  tissue	  
area	  directly	  above	  the	  hippocampus	  was	  selected	  for	  comparison	  with	  injured	  animals.	  	  In	  
both	  regions,	  strong	  ED1	  staining	  was	  seen	  in	  all	  injured	  groups.	  ED1	  staining	  was	  negligible	  
in	  the	  shams.	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FIGURE	  3-­‐8:	  DENSITOMETRY	  ANALYSIS	  OF	  ED1	  STAINING	  INTENSITY	  IN	  THE	  IPSILATERAL	  
CORTICAL	  TISSUE	  AND	  IPSILATERAL	  DENTATE	  GYRUS	  OF	  AGED	  RATS	  (20	  MONTHS).	  	  	  
Values	  are	  given	  as	  percent	  of	  ROI	  area	  occupied	  by	  the	  positively	  labeled	  cells.	  	  (A)	  In	  the	  
aged	  rat	  cortical	  tissue,	  both	  minocycline	  treatment	  groups	  had	  lower	  intensity	  of	  ED1+	  
staining	  compared	  to	  vehicles	  and	  was	  significant	  in	  the	  4-­‐hr	  treatment	  group	  (*p<0.05).	  	  	  
Similarly,	  in	  the	  DG	  both	  minocylcine	  groups	  had	  less	  ED1	  staining	  compared	  to	  vehicle	  
group,	  but	  did	  not	  research	  statistical	  significance	  (B).	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EFFECT	  OF	  MINOCYCLINE	  ON	  MICROGLIA	  STAINING	  IN	  YOUNG	  AND	  
AGED	  RATS	  FOLLOWING	  CCI	  –	  OX6	  
	   OX6	  is	  another	  general	  macrophage	  marker,	  which	  identifies	  an	  antigen	  on	  the	  
major	  histocompatibility	  complex	  (MHC)	  class	  II	  that	  is	  present	  on	  antigen-­‐presenting	  cells,	  
including	  microglia	  and	  macrophages.	  	  In	  the	  sham	  animals	  in	  both	  young	  and	  aged	  groups,	  
very	  little	  OX6+	  staining	  was	  found	  (Figures	  3-­‐9	  and	  3-­‐11).	  	  After	  injury,	  OX6+	  cells	  have	  the	  
morphology	  of	  activated	  microglia	  (i.e.	  amoeboid),	  and	  the	  density	  of	  OX6+	  microglia	  is	  
higher	  at	  the	  site	  of	  injury	  (Folkersma	  et	  al.	  2011).	  	  In	  the	  cortex,	  the	  vehicles	  had	  the	  
heaviest	  amount	  of	  staining	  compared	  to	  the	  minocycline	  treatment	  groups,	  in	  both	  age	  
groups	  (Figures	  3-­‐9	  and	  3-­‐11).	  	  In	  vehicles,	  the	  staining	  was	  mostly	  diffuse	  in	  the	  cortex,	  but	  
in	  the	  minocycline	  treatment	  groups	  staining	  was	  primarily	  only	  seen	  at	  the	  cavity	  edge.	  	  In	  
the	  dentate	  gyrus,	  staining	  appeared	  sparse	  and	  non-­‐localized,	  in	  both	  age	  groups	  (Figures	  
3-­‐9	  and	  3-­‐11).	  
	  	   Densitometry	  analysis	  found	  that	  in	  young	  animals,	  the	  two	  minocycline	  treatment	  
groups	  had	  significantly	  reduced	  OX6+	  staining	  densities	  compared	  to	  the	  vehicles	  (p=0.03,	  
for	  both,	  Figure	  3-­‐10).	  	  There	  was	  no	  difference	  in	  staining	  between	  the	  two	  minocycline	  
treatment	  groups.	  	  In	  the	  dentate	  gyrus,	  the	  vehicle	  group	  had	  the	  highest	  density	  of	  OX6+	  
staining,	  and	  the	  two	  minocycline	  treatment	  groups	  both	  had	  lower	  densities	  (Figure	  3-­‐10).	  
	   In	  the	  cortex	  of	  aged	  animals,	  both	  of	  the	  minocycline	  treatment	  groups	  had	  
significantly	  lower	  OX6+	  cell	  densities	  compared	  to	  vehicles	  (p=0.012	  for	  30-­‐minute	  group,	  
p=0.017	  for	  4-­‐hour	  group)	  (Figure	  3-­‐12).	  	  There	  were	  no	  significant	  differences	  between	  the	  
two	  minocycline	  treatment	  groups.	  	  In	  the	  hippocampus	  of	  aged	  animals,	  we	  observed	  no	  
significant	  differences	  in	  staining	  densities	  among	  any	  of	  the	  injury	  groups	  (Figure	  3-­‐12).	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   A	  comparison	  between	  the	  two	  age	  groups	  was	  also	  made	  using	  each	  treatment	  
group	  in	  both	  ROIs.	  	  There	  were	  no	  statistically	  significant	  differences	  between	  the	  age	  
groups	  in	  any	  of	  the	  animal	  groups.	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FIGURE	  3-­‐9:	  PATTERN	  OF	  OX6+	  STAINING	  IN	  THE	  PERI-­‐LESION	  CORTEX	  AND	  IPSILATERAL	  
DENTATE	  GYRUS	  (DG)	  IN	  YOUNG	  (3M)	  ANIMALS	  AT	  3	  DAYS	  POST-­‐INJURY.	  	  	  
Representative	  micrograph	  images	  of	  OX6	  staining	  in	  the	  peri-­‐lesion	  cortical	  region	  (upper	  
panels)	  and	  the	  ipsilateral	  DG	  (lower	  panels)	  from	  shams	  (N=3),	  and	  injured	  animals	  treated	  
with	  vehicle	  (N=5),	  minocycline	  beginning	  at	  30	  minutes	  after	  injury	  (N=6),	  and	  minocycline	  
beginning	  at	  4	  hours	  after	  injury	  (N=4).	  	  For	  the	  sham	  animal,	  a	  representative	  cortical	  tissue	  
area	  directly	  above	  the	  hippocampus	  was	  selected	  for	  comparison	  with	  injured	  animals.	  	  
Strong	  OX6	  staining	  was	  seen	  in	  all	  injured	  groups	  in	  the	  cortical	  region.	  	  In	  the	  DG,	  OX6	  
staining	  was	  found	  in	  the	  vehicle	  group.	  	  OX6	  staining	  was	  negligible	  in	  the	  shams.	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FIGURE	  3-­‐10:	  DENSITOMETRY	  ANALYSIS	  OF	  OX6	  LABELING	  INTENSITY	  IN	  THE	  IPSILATERAL	  
CORTICAL	  TISSUE	  AND	  IPSILATERAL	  DENTATE	  GYRUS	  OF	  YOUNG	  RATS	  (3	  MONTHS).	  	  	  
Values	  are	  given	  as	  percent	  of	  ROI	  area	  occupied	  by	  the	  positively	  labeled	  cells.	  	  (A)	  In	  the	  
cortical	  tissue	  of	  young	  animals,	  both	  minocycline	  treatment	  groups	  had	  significantly	  less	  
OX6+	  staining	  compared	  to	  vehicles	  (*p<0.05).	  (B)	  In	  the	  hippocampus	  of	  young	  animals,	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FIGURE	  3-­‐11:	  PATTERN	  OF	  OX6+	  STAINING	  IN	  THE	  PERI-­‐LESION	  CORTEX	  AND	  IPSILATERAL	  
DENTATE	  GYRUS	  (DG)	  IN	  AGED	  (20M)	  ANIMALS	  AT	  3	  DAYS	  POST-­‐INJURY.	  	  	  
Representative	  micrograph	  images	  of	  OX6	  staining	  in	  the	  peri-­‐lesion	  cortical	  region	  (upper	  
panels)	  and	  the	  ipsilateral	  DG	  (lower	  panels)	  from	  shams	  (N=2),	  and	  injured	  animals	  treated	  
with	  vehicle	  (N=4),	  minocycline	  beginning	  at	  30	  minutes	  after	  injury	  (N=4),	  and	  minocycline	  
beginning	  at	  4	  hours	  after	  injury	  (N=4).	  	  For	  the	  sham	  animal,	  a	  representative	  cortical	  tissue	  
area	  directly	  above	  the	  hippocampus	  was	  selected	  for	  comparison	  with	  injured	  animals.	  
Strong	  OX6	  staining	  was	  seen	  in	  injured	  vehicle	  group	  in	  the	  cortical	  region,	  both	  
minocycline	  treated	  groups	  had	  a	  few	  scattered	  OX6+	  cells.	  	  In	  the	  DG,	  OX6	  stained	  cells	  
were	  found	  scattered	  in	  the	  DG	  in	  all	  injury	  groups.	  	  OX6	  staining	  was	  negligible	  in	  the	  
shams.	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FIGURE	  3-­‐12:	  DENSITOMETRY	  ANALYSIS	  OF	  OX6	  CELL	  LABELING	  IN	  THE	  IPSILATERAL	  
CORTICAL	  TISSUE	  AND	  IPSILATERAL	  DENTATE	  GYRUS	  OF	  AGED	  RATS	  (20	  MONTHS).	  	  	  
Values	  are	  given	  as	  percent	  of	  ROI	  area	  occupied	  by	  the	  positively	  labeled	  cells.	  	  (A)	  In	  the	  
cortical	  tissue	  of	  aged	  animals,	  the	  OX6+	  staining	  density	  was	  significantly	  lower	  (*p<0.05)	  in	  
both	  minocycline	  treatment	  groups,	  compared	  to	  vehicle-­‐treated	  animals.	  (B)	  In	  the	  dentate	  
gyrus	  of	  aged	  animals,	  there	  were	  no	  significant	  differences	  in	  OX6+	  cell	  area	  densities	  
among	  any	  of	  the	  groups	  compared.	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EFFECT	  OF	  MINOCYCLINE	  ON	  M2	  PHENOTYPE	  IN	  YOUNG	  AND	  AGED	  
RATS	  FOLLOWING	  CCI	  INJURY	  
	   To	  determine	  whether	  any	  changes	  in	  microglial	  phenotype	  occurred	  with	  
minocycline	  treatment	  in	  both	  young	  and	  aged	  rats	  undergoing	  CCI	  injury,	  we	  stained	  
sections	  for	  Arginase	  1	  expression.	  	  Arg1	  antibody	  reacts	  with	  arginase,	  an	  enzyme	  involved	  
in	  the	  metabolism	  of	  arginine,	  and	  is	  a	  specific	  marker	  for	  M2	  cells.	  	  However,	  arginase	  1	  is	  
also	  known	  to	  be	  weakly	  expressed	  in	  astrocytes	  (as	  well	  as	  some	  neurons)	  in	  the	  normal	  rat	  
CNS	  (Ahn	  et	  al.	  2012).	  	  In	  both	  young	  and	  aged	  animals,	  very	  little	  ARG1+	  staining	  was	  found	  
in	  the	  cortex	  and	  DG	  of	  shams	  (Figures	  3-­‐13	  and	  3-­‐15).	  	  In	  the	  cortex	  in	  injury	  groups,	  Arg1+	  
cells	  were	  mostly	  localized	  around	  the	  injury	  cavity	  (Figures	  3-­‐13	  and	  3-­‐15).	  	  In	  the	  dentate	  
gyrus,	  staining	  is	  sparse	  and	  scattered	  across	  the	  region	  (Figures	  3-­‐13	  and	  3-­‐15).	  	  	  
In	  the	  cortex	  of	  young	  animals,	  all	  injury	  groups	  were	  observed	  to	  have	  higher	  
ARG1+	  staining	  densities	  than	  sham	  (Figure	  3-­‐14).	  	  However,	  there	  were	  no	  statistically	  
significant	  differences	  among	  any	  of	  the	  injury	  groups	  (vehicle,	  30-­‐minute	  minocycline,	  and	  
4-­‐hour	  minocycline).	  	  In	  the	  hippocampus	  of	  young	  animals,	  there	  were	  also	  no	  significant	  
differences	  among	  any	  of	  the	  injury	  groups,	  meaning	  there	  was	  no	  effect	  with	  minocycline	  
treatment.	  	  In	  the	  aged	  animals,	  increased	  ARG1+	  cell	  density	  was	  statistically	  significant	  in	  
vehicles	  and	  the	  30-­‐minute	  minocycline	  group,	  when	  compared	  to	  shams.	  	  However,	  there	  
were	  no	  significant	  differences	  among	  the	  injury	  groups.	  	  In	  the	  hippocampus	  of	  the	  aged	  
animals,	  the	  ARG1+	  staining	  densities	  of	  the	  injury	  groups	  were	  not	  significantly	  different	  
from	  shams.	  	  Although,	  the	  ARG1+	  cell	  density	  was	  significantly	  lower	  in	  the	  4-­‐hour	  
minocycline	  treatment	  group	  when	  compared	  to	  vehicles	  (p=0.014).	  	  There	  were	  no	  
differences	  in	  staining	  between	  the	  two	  minocycline	  treatment	  groups	  or	  between	  the	  30-­‐
minute	  minocycline	  treatment	  group	  and	  vehicles.	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   When	  comparing	  the	  two	  age	  groups,	  we	  found	  no	  significant	  differences	  in	  Arg1	  
staining	  intensity	  between	  any	  of	  the	  animal	  groups	  in	  the	  cortical	  tissue.	  	  Examining	  the	  
hippocampus,	  we	  found	  a	  significant	  difference	  between	  the	  two	  4-­‐hour	  minocycline	  
treatment	  groups,	  with	  the	  aged	  group	  having	  lower	  staining	  density	  than	  the	  young.	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FIGURE	  3-­‐13:	  PATTERN	  OF	  M2	  MARKER	  ARG1+	  STAINING	  IN	  THE	  PERI-­‐LESION	  CORTEX	  
AND	  IPSILATERAL	  DENTATE	  GYRUS	  (DG)	  IN	  YOUNG	  (3M)	  ANIMALS	  AT	  3	  DAYS	  POST-­‐
INJURY.	  	  	  
Representative	  micrograph	  images	  of	  ARG1	  staining	  in	  the	  peri-­‐lesion	  cortical	  region	  (upper	  
panels)	  and	  the	  ipsilateral	  DG	  (lower	  panels)	  from	  shams	  (N=2),	  and	  injured	  animals	  treated	  
with	  vehicle	  (N=5),	  minocycline	  beginning	  at	  30	  minutes	  after	  injury	  (N=4),	  and	  minocycline	  
beginning	  at	  4	  hours	  after	  injury	  (N=4).	  	  For	  the	  sham	  animal,	  a	  representative	  cortical	  tissue	  
area	  directly	  above	  the	  hippocampus	  was	  selected	  for	  comparison	  with	  injured	  animals.	  	  
Strong	  ARG1	  staining	  was	  seen	  in	  injured	  vehicle	  group	  in	  the	  cortical	  region,	  both	  
minocycline	  treated	  groups	  had	  a	  few	  scattered	  ARG1+	  cells.	  	  In	  the	  DG,	  ARG1	  stained	  cells	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FIGURE	  3-­‐14:	  DENSITOMETRY	  ANALYSIS	  OF	  ARG1	  LABELING	  IN	  THE	  IPSILATERAL	  CORTICAL	  
TISSUE	  AND	  IPSILATERAL	  DENTATE	  GYRUS	  OF	  YOUNG	  RATS	  (3	  MONTHS).	  	  	  
Values	  are	  given	  as	  percent	  of	  ROI	  area	  occupied	  by	  the	  positively	  labeled	  cells.	  (A)	  In	  the	  
cortical	  tissue	  of	  young	  rats,	  there	  was	  negligible	  ARG1+	  staining	  in	  shams.	  	  The	  mean	  
ARG1+	  staining	  density	  was	  higher	  in	  all	  three	  injury	  groups.	  	  The	  differences	  among	  the	  
vehicle,	  Mino-­‐30min,	  and	  Mino-­‐4hr	  groups	  were	  not	  significant.	  	  (B)	  In	  the	  hippocampus	  of	  
young	  rats,	  there	  were	  no	  significant	  differences	  in	  ARG1+	  cell	  area	  densities	  among	  any	  of	  
the	  injury	  groups.	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FIGURE	  3-­‐13:	  PATTERN	  OF	  M2	  MARKER	  ARG1+	  STAINING	  IN	  THE	  PERI-­‐LESION	  CORTEX	  
AND	  IPSILATERAL	  DENTATE	  GYRUS	  (DG)	  IN	  AGED	  (20M)	  ANIMALS	  AT	  3	  DAYS	  POST-­‐
INJURY.	  	  	  
Representative	  micrograph	  images	  of	  ARG1	  staining	  in	  the	  peri-­‐lesion	  cortical	  region	  (upper	  
panels)	  and	  the	  ipsilateral	  DG	  (lower	  panels)	  from	  shams	  (N=2),	  and	  injured	  animals	  treated	  
with	  vehicle	  (N=4),	  minocycline	  beginning	  at	  30	  minutes	  after	  injury	  (N=4),	  and	  minocycline	  
beginning	  at	  4	  hours	  after	  injury	  (N=4).	  	  For	  the	  sham	  animal,	  a	  representative	  cortical	  tissue	  
area	  directly	  above	  the	  hippocampus	  was	  selected	  for	  comparison	  with	  injured	  animals.	  	  
Strong	  ARG1	  staining	  was	  seen	  in	  injured	  vehicle	  group	  in	  the	  cortical	  region,	  both	  
minocycline	  treated	  groups	  had	  a	  few	  scattered	  ARG1+	  cells.	  	  In	  the	  DG,	  ARG1	  stained	  cells	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FIGURE	  3-­‐16:	  DENSITOMETRY	  ANALYSIS	  OF	  ARG1	  LABELING	  IN	  THE	  IPSILATERAL	  CORTICAL	  
TISSUE	  AND	  IPSILATERAL	  DENTATE	  GYRUS	  OF	  AGED	  RATS	  (20	  MONTHS).	  	  	  
Values	  are	  given	  as	  percent	  of	  ROI	  area	  occupied	  by	  the	  positively	  labeled	  cells.	  	  (A)	  In	  the	  
cortical	  tissue	  of	  aged	  rats,	  the	  ARG1+	  staining	  in	  shams	  was	  also	  negligible.	  	  There	  were	  
also	  no	  significant	  differences	  in	  ARG1+	  cell	  area	  densities	  among	  the	  three	  injury	  groups.	  	  
(B)	  In	  the	  hippocampus	  of	  aged	  rats,	  there	  were	  no	  significant	  differences	  between	  the	  
injury	  groups	  and	  shams.	  	  However,	  the	  ARG1+	  staining	  density	  in	  the	  Mino-­‐4hr	  group	  was	  
significantly	  lower	  than	  the	  vehicle-­‐treated	  group	  (*p<0.05).	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CO-­‐LOCALIZATION	  OF	  MICROGLIAL	  MARKERS	  
	   To	  determine	  whether	  the	  changes	  in	  microglial	  activation	  are	  due	  to	  phenotype	  
switching	  or	  due	  to	  the	  generation	  of	  new	  cells,	  we	  double-­‐labeled	  sections	  for	  BrdU	  and	  
one	  of	  the	  aforementioned	  microglial	  cell	  markers.	  	  BrdU	  is	  a	  marker	  for	  newly	  proliferating	  
cells,	  and	  co-­‐localization	  with	  one	  of	  the	  other	  markers	  would	  tell	  us	  that	  the	  
microglia/macrophage	  cell	  is	  newly	  formed.	  	  Double-­‐labeling	  was	  performed	  on	  at	  least	  one	  
section	  from	  each	  injury	  group	  (vehicle,	  30-­‐minute	  minocycline,	  and	  4-­‐hour	  minocycline)	  in	  
both	  age	  groups,	  but	  damage	  to	  the	  sections	  and	  poor	  staining	  prevented	  some	  of	  them	  
from	  being	  used.	  	  Because	  BrdU+	  cells	  were	  mostly	  observed	  in	  the	  cortical	  regions	  around	  
the	  injury,	  therefore,	  examination	  of	  double	  labeling	  was	  performed	  only	  in	  this	  region.	  	  
	  	   We	  found	  that	  40%	  of	  the	  newly	  proliferating	  cells	  in	  the	  vehicle-­‐treated	  animals	  
also	  stained	  positively	  for	  Iba1,	  compared	  to	  46%	  in	  the	  minocycline-­‐treated	  group.	  	  We	  also	  
observed	  that	  10%	  of	  the	  BrdU+	  cells	  in	  the	  vehicle	  animals	  were	  ED1+,	  compared	  to	  15%	  in	  
minocycline-­‐treated	  animals.	  	  We	  saw	  that	  in	  minocycline-­‐treated	  animals	  around	  17%	  
newly	  proliferating	  cells	  co-­‐labeled	  with	  ARG1,	  however,	  we	  were	  not	  able	  to	  compare	  the	  
result	  to	  vehicles	  due	  to	  poor	  morphology.	  
	   We	  evaluated	  ARG1/ED1	  double-­‐labeling	  to	  determine	  whether	  the	  M2	  cell-­‐type	  
marker	  co-­‐localized	  with	  the	  general	  microglia	  cell	  marker,	  and	  found	  that	  the	  two	  markers	  
did	  have	  overlap.	  	  However,	  this	  labeling	  was	  only	  performed	  in	  a	  vehicle	  section,	  so	  no	  
comparison	  with	  treatment	  could	  be	  made.	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FIGURE	  3-­‐17:	  IMMUNOFLUORESCENT	  DOUBLE	  LABELING	  IN	  THE	  PERI-­‐CONTUSIONAL	  
CORTEX.	  	  	  
Representative	  confocal	  micrographs	  of	  double	  labeling	  examined.	  A)	  BrdU	  and	  Iba1;	  B)	  ED1	  
and	  BrdU;	  C)	  BrdU	  and	  ARG1;	  D)	  ED1	  and	  ARG1.	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DISCUSSION	  
	  
SUMMARY	  OF	  RESULTS	  
	   This	  study	  examined	  the	  effects	  of	  short-­‐term	  minocycline	  treatment	  on	  the	  
inflammatory	  response	  in	  rats	  at	  the	  age	  of	  3	  months	  or	  20	  months	  following	  controlled	  
cortical	  impact	  (CCI)	  injury.	  	  Two	  treatment	  groups	  were	  compared	  to	  controls,	  which	  
included	  shams	  and	  vehicle-­‐administered	  animals.	  	  Group	  one	  animals	  received	  the	  first	  
dose	  of	  minocycline	  beginning	  at	  30	  minutes	  post-­‐injury	  (30-­‐minute	  minocycline	  group),	  
while	  the	  other	  group	  of	  animals	  received	  the	  first	  dose	  at	  4	  hours	  post-­‐injury	  (4-­‐hour	  
minocycline	  group).	  	  Both	  groups	  underwent	  the	  same	  subsequent	  minocycline	  injection	  
schedule.	  	  All	  animals	  were	  sacrificed	  at	  3	  days	  post	  injury,	  so	  that	  the	  acute	  inflammatory	  
response	  could	  be	  evaluated.	  	  In	  addition,	  two	  age	  groups	  were	  compared:	  young	  rats	  (3-­‐
month-­‐old)	  and	  aged	  rats	  (20-­‐month-­‐old).	  
	   In	  order	  to	  assess	  the	  inflammatory	  response,	  three	  general	  microglia/macrophage	  
markers	  were	  used:	  Iba1,	  ED1,	  and	  OX6.	  	  We	  also	  used	  the	  M2	  cell	  type	  marker	  ARG1	  to	  
evaluate	  minocycline’s	  effect	  on	  the	  phenotype	  of	  activated	  microglia	  after	  injury.	  	  We	  have	  
also	  tested	  two	  M1	  markers	  (iNOS	  and	  CD86)	  and	  another	  M2	  marker,	  CD206.	  	  However,	  
these	  antibodies	  did	  not	  work	  in	  immunohistochemistry	  on	  the	  rat	  brain.	  	  	  In	  this	  study,	  we	  
focused	  on	  regions	  of	  the	  peri-­‐lesion	  cortex	  and	  the	  dentate	  gyrus	  of	  the	  ipsilateral	  
hippocampus.	  	  In	  young	  animals,	  minocycline	  treatment	  significantly	  reduced	  microglial	  
staining	  intensity	  in	  the	  cortical	  tissue	  surrounding	  the	  injury	  site,	  as	  evidenced	  by	  OX6	  
staining.	  	  Changes	  in	  staining	  intensity	  in	  cortical	  tissue	  were	  not	  significant	  in	  ED1	  or	  Iba1	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staining.	  	  In	  the	  dentate	  gyrus	  of	  young	  animals,	  minocycline	  treatment	  did	  not	  significantly	  
decrease	  microglial	  staining	  intensity	  with	  all	  markers.	  	  	  
In	  the	  aged	  animals,	  in	  the	  cortical	  tissue,	  minocycline	  treatment	  significantly	  
reduced	  microglial	  staining	  intensity	  compared	  to	  vehicle-­‐treated	  animals	  in	  all	  three	  pan-­‐
inflammatory	  markers.	  	  Between	  the	  two	  treatment	  regimes,	  the	  4-­‐hour	  minocycline	  
treatment	  group	  had	  lower	  Iba1	  staining	  compared	  to	  the	  30-­‐minute	  group.	  	  In	  the	  
hippocampus	  of	  the	  aged	  animals,	  reduction	  of	  Iba1	  and	  Ed1	  staining	  was	  observed	  in	  
minocylcine	  treated	  groups	  particularly	  in	  the	  4-­‐hour	  treatment	  group.	  	  In	  both	  young	  and	  
aged	  animals,	  M2	  marker	  Arg1	  expression	  was	  increased	  in	  all	  injured	  groups,	  but	  not	  
significantly	  changed	  in	  both	  minocycline	  treatment	  regimes	  compared	  to	  vehicle	  treated	  
group.	  	  
	   In	  comparing	  staining	  intensity	  between	  the	  two	  age	  groups,	  we	  found	  that	  
minocycline	  treatment,	  particularly	  treatment	  beginning	  at	  4hr	  post	  injury,	  had	  significant	  
reduction	  in	  the	  expression	  of	  inflammatory	  cells	  markers	  in	  the	  aged	  animals	  compare	  to	  
their	  younger	  counterparts.	  	  	  
	  
CCI	  INJURY	  INDUCES	  AN	  INFLAMMATORY	  RESPONSE	  IN	  BOTH	  THE	  
PERI-­‐CONTUSIONAL	  CORTICAL	  TISSUE	  AND	  THE	  DENTATE	  GYRUS	  IN	  
YOUNG	  AND	  AGED	  RATS	  
	   The	  presence	  of	  a	  robust	  secondary	  inflammatory	  response	  after	  TBI	  has	  been	  well	  
described,	  especially	  in	  the	  acute	  stage.	  	  The	  inflammatory	  response	  is	  characterized	  by	  the	  
activation	  of	  resident	  microglia	  and	  the	  infiltration	  of	  peripheral	  leukocytes	  through	  the	  
now	  permeable	  blood-­‐brain	  barrier	  (BBB).	  	  Increased	  staining	  in	  regions	  of	  the	  brain	  for	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microglial	  markers,	  like	  Iba1,	  after	  injury	  suggests	  the	  presence	  of	  an	  inflammatory	  response	  
and	  microglial	  activation	  (Sandhir	  et	  al.	  2008).	  	  When	  activated	  in	  response	  to	  a	  mechanical	  
or	  chemical	  stimulus,	  these	  immune	  cells	  secrete	  cytokines,	  and	  elevations	  in	  their	  
concentrations	  are	  indicators	  of	  a	  response	  to	  injury.	  	  Levels	  of	  both	  pro-­‐	  and	  anti-­‐
inflammatory	  cytokines,	  including	  IL-­‐1α,	  IL-­‐1β,	  IL-­‐6,	  and	  TNF-­‐α,	  can	  rise	  significantly	  within	  
hours	  after	  injury,	  in	  the	  peri-­‐contusional	  cortex	  (Mukherjee	  et	  al.	  2011),	  as	  well	  as	  in	  the	  
ipsilateral	  hippocampus	  (Harting	  et	  al.	  2008).	  	  
In	  the	  current	  study,	  Iba1	  staining	  revealed	  higher	  microglia	  cell	  densities	  in	  injured,	  
vehicle-­‐administered	  animals	  when	  compared	  to	  shams,	  which	  was	  statistically	  significant	  in	  
young	  and	  aged	  cortical	  tissue,	  as	  well	  as	  in	  the	  aged	  hippocampus	  (Figures	  3-­‐2	  and	  3-­‐4).	  	  
Staining	  for	  ED1	  and	  OX6	  also	  demonstrated	  increased	  microglia	  cell	  densities	  in	  vehicles	  
compared	  to	  shams.	  	  Consistent	  with	  published	  studies,	  our	  data	  indicates	  that	  the	  CCI	  
injury	  initiated	  an	  inflammatory	  response	  in	  the	  peri-­‐contusional	  cortex	  as	  well	  as	  in	  the	  
hippocampus,	  as	  indicated	  by	  elevated	  densities	  of	  microglia/macrophages	  in	  these	  regions	  
following	  injury	  in	  vehicle	  treated	  animals.	  
	   This	  study	  also	  compared	  the	  two	  age	  groups	  to	  each	  other.	  	  Aging	  has	  been	  
associated	  with	  increased	  systemic	  inflammation,	  which	  is	  believed	  to	  contribute	  to	  an	  
exaggerated	  inflammatory	  response	  after	  injury	  (Sandhir	  et	  al.	  2008;	  Timaru-­‐Kast	  et	  al.	  
2001).	  	  However,	  our	  comparison	  of	  cell	  densities	  in	  the	  sham	  and	  vehicle	  groups	  between	  
the	  young	  and	  aged	  animals	  revealed	  no	  significant	  differences.	  	  Our	  findings	  did	  not	  
indicate	  higher	  levels	  of	  inflammatory	  cell	  response	  in	  aged	  animals	  likely	  due	  to	  the	  
quantification	  methods	  we	  used.	  	  More	  accurate	  assessment	  of	  protein	  expression,	  by	  a	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method	  such	  as	  Western	  blotting,	  or	  more	  detailed	  analysis	  of	  morphological	  changes	  are	  
needed	  for	  such	  comparison.	  
	  
ACUTE	  MINOCYCLINE	  TREATMENT	  ATTENUATES	  THE	  INFLAMMATORY	  
RESPONSE	  IN	  YOUNG	  AND	  AGED	  RATS	  FOLLOWING	  CCI	  INJURY	  
The	  anti-­‐inflammatory	  properties	  of	  minocycline	  are	  well	  documented.	  	  The	  drug	  is	  
known	  to	  attenuate	  production	  of	  reactive	  oxygen	  species	  (ROS),	  as	  well	  as	  secretion	  of	  pro-­‐
inflammatory	  cytokines	  from	  activated	  cells	  (Sanchez	  Mejia	  et	  al.	  2001).	  	  Minocycline	  has	  
also	  been	  shown	  to	  inhibit	  recruitment	  of	  microglia/macrophages	  to	  affected	  sites	  in	  the	  
brain	  (Ng	  et	  al.	  2012),	  thereby	  reducing	  the	  degree	  of	  the	  inflammatory	  response	  induced	  
after	  injury.	  	  Minocycline’s	  beneficial	  effects	  seem	  to	  be	  related	  to	  the	  attenuation	  of	  
microglial	  activation	  (Fan	  et	  al.	  2005)	  and	  proliferation	  (Tikka	  et	  al.	  2001).	  	  
Consistent	  with	  these	  findings,	  the	  current	  study	  found	  that	  minocycline-­‐treated	  
animals	  had	  significantly	  reduced	  microglial	  staining	  intensity	  in	  both	  age	  groups,	  and	  was	  
particularly	  significant	  in	  the	  aged	  group.	  	  These	  reductions	  in	  microglia/macrophage	  
recruitment	  indicate	  a	  suppression	  of	  the	  secondary	  neuroinflammation	  following	  the	  CCI	  
injury.	  	  
As	  we	  did	  not	  see	  any	  increase	  in	  the	  inflammatory	  response	  in	  aged	  animals	  
compared	  to	  young,	  we	  cannot	  conclude	  that	  the	  significant	  reduction	  in	  staining	  with	  
minocycline	  treatment	  is	  due	  to	  a	  suppression	  of	  elevated	  age-­‐related	  systemic	  
inflammation.	  	  However,	  using	  a	  different	  form	  of	  assessment,	  such	  as	  level	  of	  cytokine	  or	  
cell-­‐surface	  marker	  expression,	  may	  give	  a	  more	  accurate	  depiction	  of	  the	  cellular	  changes	  
in	  the	  aging	  brain.	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ACUTE	  MINOCYCLINE	  TREATMENT	  DOES	  NOT	  ENHANCE	  M2	  
PHENOTYPE	  IN	  YOUNG	  OR	  AGED	  RATS	  FOLLOWING	  CCI	  INJURY	  
	   During	  the	  TBI-­‐induced	  secondary	  inflammatory	  response,	  microglia	  are	  the	  primary	  
mediators.	  	  They	  play	  a	  defensive	  role,	  phagocytizing	  debris	  and	  pathogens	  and	  releasing	  
signals	  to	  recruit	  and	  activate	  more	  microglia	  and	  other	  leukocytes,	  as	  well	  as	  a	  protective	  
role,	  secreting	  anti-­‐inflammatory	  cytokines	  and	  growth	  factors	  to	  enhance	  repair	  and	  
neurogenesis.	  	  Microglia/macrophages	  exhibiting	  a	  defensive,	  pro-­‐inflammatory	  phenotype	  
are	  commonly	  referred	  to	  as	  M1	  type	  cells,	  whereas	  those	  exhibiting	  protective,	  anti-­‐
inflammatory	  properties	  are	  known	  as	  M2	  type	  cells.	  	  Recovery	  after	  injury	  requires	  a	  
balance	  between	  these	  two	  phenotypes.	  	  Enhancement	  of	  the	  M1	  phenotype	  and	  an	  
impaired	  ability	  to	  promote	  the	  M2	  phenotype	  have	  been	  suggested	  as	  reasons	  for	  poorer	  
outcomes	  after	  injury	  in	  aged	  individuals	  compared	  to	  the	  young	  (Kumar	  et	  al.	  2013).	  	  	  
Several	  studies	  have	  found	  that	  suppression	  of	  the	  inflammatory	  response,	  using	  a	  
drug	  like	  minocycline,	  correlates	  with	  improved	  outcome	  and	  recovery	  and	  reduced	  lesion	  
size	  (Ng	  et	  al.	  2012;	  Bye	  et	  al.	  2007).	  	  While	  much	  is	  known	  about	  the	  neuroprotective	  and	  
anti-­‐inflammatory	  effects	  of	  minocycline,	  little	  is	  understood	  regarding	  its	  effect	  on	  the	  
phenotype	  of	  reactive	  microglia	  and	  macrophages.	  	  This	  study	  aimed	  to	  examine	  the	  effect	  
of	  minocycline	  treatment	  on	  the	  density	  of	  M2	  cells	  present	  in	  the	  peri-­‐contusional	  cortex	  
and	  the	  ipsilateral	  hippocampus,	  in	  the	  acute	  stage	  after	  CCI	  injury.	  	  	  
Arginase	  is	  an	  enzyme	  involved	  in	  the	  metabolism	  of	  arginine,	  driving	  the	  reaction	  
toward	  production	  of	  proline	  and	  other	  molecules	  involved	  in	  cellular	  repair	  and	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regeneration.	  	  As	  such,	  arginine	  expression	  is	  up-­‐regulated	  in	  M2,	  alternatively	  activated,	  
microglia/macrophages,	  making	  it	  a	  suitable	  marker	  for	  identifying	  the	  anti-­‐inflammatory	  
cell	  type.	  	  	  
	   While	  ARG1+	  staining	  density	  was	  elevated	  in	  the	  cortex	  of	  all	  injury	  groups	  in	  both	  
young	  and	  aged	  animals,	  our	  data	  showed	  no	  significant	  differences	  between	  vehicles	  and	  
minocycline-­‐treated	  animals	  (Figures	  3-­‐14	  and	  3-­‐15).	  	  In	  the	  dentate	  gyrus,	  there	  was	  very	  
little	  staining	  in	  all	  of	  the	  groups,	  and	  there	  were	  no	  significant	  differences	  among	  any	  of	  
them	  (Figures	  3-­‐19	  and	  3-­‐20).	  	  Our	  findings	  indicate	  that	  minocycline	  treatment	  had	  no	  
effect	  on	  the	  recruitment	  of	  M2	  type	  cells	  to	  the	  injury	  site.	  	  We	  therefore	  speculate	  that	  
the	  neuro-­‐protective	  effects	  of	  minocycline	  are	  exerted	  by	  suppressing	  microglial	  activation	  
as	  a	  whole,	  and	  not	  by	  enhancing	  expression	  of	  the	  M2	  phenotype.	  
Other	  studies	  have	  documented	  suppression	  of	  pro-­‐inflammatory	  cytokine	  
expression	  with	  minocycline	  treatment	  (Bye	  et	  al.	  2007).	  	  In	  a	  recent	  model	  of	  amyotrophic	  
lateral	  sclerosis	  (ALS)	  in	  mice,	  it	  was	  shown	  that	  minocycline	  treatment	  reduced	  expression	  
of	  M1	  markers,	  but	  had	  no	  effect	  on	  expression	  of	  the	  M2	  phenotype	  (Kobayashi	  et	  al.	  
2013).	  	  Expanding	  this	  study	  to	  include	  a	  marker	  for	  the	  M1	  cell	  type	  could	  further	  elucidate	  
the	  effect	  of	  injury	  and	  minocycline	  treatment	  on	  the	  M1/M2	  balance.	  	  	  
Our	  double-­‐labeling	  study	  also	  found	  that	  not	  all	  cells	  labeled	  for	  ARG1	  also	  labeled	  
for	  ED1,	  indicating	  that	  ARG1	  also	  picked	  up	  weak	  staining	  in	  other	  cells,	  likely	  astrocytes.	  	  
This	  could	  be	  confirmed	  with	  further	  double-­‐labeling	  of	  ARG1	  with	  an	  astrocyte-­‐specific	  cell	  
marker,	  such	  as	  GFAP.	  	  The	  role	  of	  astrocytes	  in	  the	  inflammatory	  response	  cannot	  be	  
ignored,	  as	  they	  are	  similarly	  activated	  after	  TBI	  and	  release	  many	  of	  the	  same	  cytokines	  
and	  reparative	  factors	  that	  activated	  microglia	  do	  (Woodcock	  and	  Morganti-­‐Kossmann	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2013).	  	  	  Although	  microglial	  activation	  usually	  precedes	  astrocyte	  activation,	  both	  are	  noted	  
within	  the	  first	  24	  hours	  after	  injury,	  and	  should	  therefore	  be	  considered	  when	  evaluating	  
the	  acute	  response	  to	  injury	  (Sandhir	  et	  al.	  2008).	  	  Further	  investigation	  examining	  the	  role	  
and	  changes	  in	  astrocytes	  could	  also	  elucidate	  the	  effects	  of	  minocycline	  treatment	  on	  the	  
inflammatory	  response	  following	  TBI.	  
MINOCYCLINE	  TREATMENT	  DOES	  NOT	  CHANGE	  THE	  PROLIFERATION	  
RATE	  OF	  INFLAMMATORY	  CELLS	  
To	  examine	  whether	  minocycline	  affects	  proliferation	  of	  inflammatory	  cells,	  the	  
animals	  in	  our	  study	  were	  given	  pulse	  injections	  of	  BrdU	  at	  the	  last	  day	  of	  minocycline	  
treatment.	  	  We	  were	  therefore	  able	  to	  double-­‐label	  our	  sections	  for	  BrdU	  and	  microglial	  
cell-­‐type-­‐specific	  markers	  and	  evaluate	  changes	  in	  microglial	  proliferation.	  
Our	  study	  found	  a	  slightly	  higher	  rate	  of	  co-­‐labeling	  of	  BrdU	  with	  Iba1+	  or	  ED1+	  in	  
the	  injured	  cortex	  region	  in	  animals	  treated	  with	  minocycline	  as	  compared	  to	  vehicle-­‐
treated	  animals.	  	  	  As	  minocycline	  decreases	  microglia	  activation,	  this	  result	  could	  be	  due	  to	  
reduction	  of	  both	  cell	  activation	  and	  cell	  proliferation.	  	  Our	  results	  suggest	  that	  the	  effect	  of	  
minocycline	  used	  in	  our	  regime	  is	  more	  due	  to	  the	  reduction	  of	  cell	  activation.	  	  More	  precise	  
analysis	  by	  counting	  the	  number	  of	  Brdu+	  cells,	  and	  the	  number	  of	  activated	  microglial	  will	  
provide	  more	  accurate	  conclusion.	  	  	  Other	  studies	  reported	  minocycline	  acts	  by	  attenuating	  
microglial	  proliferation	  (Tikka	  et	  al.	  2001),	  however,	  a	  proliferation	  marker	  was	  not	  used	  in	  
this	  study	  therefore	  the	  term	  “proliferation”	  was	  not	  accurate.	  	  Consistent	  with	  other	  
studies	  (Fan	  et	  al.	  2005),	  our	  findings	  suggest	  that	  minocycline	  treatment	  in	  this	  case	  acted	  
by	  largely	  by	  reducing	  microglial	  activation.	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Double-­‐labeling	  of	  BrdU	  and	  ARG1	  also	  revealed	  that	  some	  of	  the	  newly	  proliferating	  
microglia	  exhibited	  the	  M2	  phenotype	  which	  may	  indicate	  generation	  of	  M2	  cells,	  after	  
minocycline	  treatment.	  	  However,	  we	  could	  not	  compare	  this	  result	  to	  vehicle-­‐treated	  
animals	  due	  to	  bad	  issue	  processing	  so	  the	  finding	  is	  inconclusive.	  	  Expanding	  this	  survey	  to	  
include	  a	  marker	  for	  the	  M1	  phenotype	  in	  the	  double-­‐labeling	  would	  be	  able	  to	  tell	  us	  more	  
about	  the	  M1/M2	  cell	  type	  prevalence	  among	  newly	  proliferating	  cells.	  	  	   	  
CONCLUSION	  
This	  study,	  consistent	  with	  previous	  research,	  found	  that	  CCI	  injury	  induced	  a	  
secondary	  inflammatory	  response	  in	  the	  acute	  stage.	  	  It	  also	  revealed	  that	  treatment	  with	  
the	  anti-­‐inflammatory	  drug	  minocycline	  attenuated	  the	  response,	  as	  evidenced	  by	  reduced	  
densities	  of	  microglia	  in	  both	  the	  peri-­‐contusional	  cortical	  tissue	  and	  the	  ipsilateral	  
hippocampus.	  	  This	  response	  was	  especially	  pronounced	  in	  the	  aged	  group,	  compared	  to	  the	  
young	  animals.	  	  However,	  analysis	  of	  changes	  to	  the	  density	  of	  the	  M2	  phenotype	  with	  
minocycline	  treatment	  revealed	  no	  differences	  when	  compared	  to	  vehicles.	  	  In	  this	  study,	  
minocycline	  treatment	  had	  no	  effect	  on	  the	  recruitment	  of	  M2	  anti-­‐inflammatory	  cells	  to	  
the	  injury	  areas.	  	  Our	  findings	  indicate	  a	  need	  for	  further	  study	  of	  the	  effects	  of	  minocycline	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